Biotech Industry Financials, Performance and Ratios
-
Industry Score
35.1 /100
Rank 80 out of 131 Industries -
Advance/Decline
158/124
-
No. of Companies282
-
Avg. Market Cap2,803
-
Price to Earning Ratio5.93
-
Price to Earning Growth Ratio0.53
-
Price to Book Ratio15.48
-
Return on Equity16.83
-
Return on Capital Employed-
-
Return on Assets5.73
-
Dividend yield 1 year %0.29 %
-
Net Profit Growth Annual YoY %61.51 %
-
Net Profit Growth Qtr YoY %99.51 %
-
Net Profit Growth Qtr QoQ %100.59 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,812.0
|
23.7
|
L
 -1.5%
H
22.9
24.6
|
L
 5.1%
H
22.4
26.3
|
L
 0.2%
H
21.6
26.3
|
L
 -6.2%
H
21.6
27.7
|
L
 92.6%
H
11.9
27.7
|
L
 152.7%
H
7.9
27.7
|
L
 -28.1%
H
7.9
37.5
|
L
H
7.9
37.6
|
| Nuvation Bio Inc (Class A) |
|
1,667.9
|
4.8
|
L
 -0.4%
H
4.7
4.9
|
L
 6.7%
H
4.1
5.2
|
L
 5.7%
H
4.1
5.3
|
L
 -16.0%
H
4.0
6.1
|
L
 128.1%
H
1.6
9.8
|
L
 195.7%
H
1.0
9.8
|
L
 -58.5%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
3,189.6
|
25.4
|
L
 2.3%
H
24.3
25.7
|
L
 -1.3%
H
24.2
26.7
|
L
 12.0%
H
20.3
28.7
|
L
 20.6%
H
18.5
28.7
|
L
 197.3%
H
7.9
28.7
|
L
 27.8%
H
6.5
28.7
|
L
 -16.7%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
274.9
|
4.0
|
L
 0.8%
H
3.9
4
|
L
 -0.5%
H
3.9
4.3
|
L
 16.4%
H
3.3
4.4
|
L
 43.8%
H
2.7
4.5
|
L
 142.1%
H
1.6
4.5
|
L
 -52.7%
H
1.2
8.6
|
L
 -74.8%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,599.6
|
5.2
|
L
 8.7%
H
4.9
5.3
|
L
 18.3%
H
4.4
5.3
|
L
 52.8%
H
3.4
5.3
|
L
 65.8%
H
2.9
5.3
|
L
 160.7%
H
1.9
6.5
|
L
 -8.2%
H
1.9
8.1
|
L
 -82.0%
H
1.9
36.1
|
L
H
1.9
71.9
|
| Adma Biologics Inc |
|
1,893.6
|
8.2
|
L
 -3.5%
H
8.0
8.9
|
L
 -22.3%
H
7.5
10.7
|
L
 -16.9%
H
7.5
11.4
|
L
 -50.3%
H
7.2
17.2
|
L
 -61.5%
H
7.2
22.4
|
L
 133.4%
H
3.1
25.7
|
L
 369.5%
H
1.0
25.7
|
L
 33.5%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,210.2
|
13.8
|
L
 -6.0%
H
13.6
14.5
|
L
 -3.2%
H
13.0
15.1
|
L
 -6.9%
H
12.4
15.2
|
L
 -12.4%
H
12
17.0
|
L
 49.0%
H
8.5
20.8
|
L
 109.2%
H
2.3
20.8
|
L
 -60.5%
H
2.3
43.4
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.1
|
0.1
|
L
H
0.1
0.1
|
L
 -40%
H
0.1
0.2
|
L
 -76.9%
H
0.1
0.5
|
L
 -97.7%
H
0.1
6.4
|
L
 -100.0%
H
0.1
1979.8
|
L
 -100.0%
H
0.1
9256960000
|
L
 -100.0%
H
0.1
10000000000
|
L
H
0.1
10000000000
|
| Agenus Inc |
|
158.7
|
3.8
|
L
 1.9%
H
3.7
3.9
|
L
 -0.5%
H
3.7
4.3
|
L
 -9.1%
H
3.6
5.1
|
L
 29.9%
H
2.8
5.1
|
L
 25.7%
H
2.7
7.3
|
L
 -88.0%
H
1.4
196
|
L
 -93.7%
H
1.4
196
|
L
 -93.5%
H
1.4
196
|
| Aeglea BioTherapeutics Inc |
|
303.8
|
75.0
|
L
 2.7%
H
72.4
75.9
|
L
 8.1%
H
67.2
75.9
|
L
 44.4%
H
50.9
76
|
L
 113.7%
H
32.4
76
|
L
 394.3%
H
13.9
76
|
L
 1799.7%
H
2.7
76
|
L
 -58.5%
H
2.7
212.5
|
L
 -65.5%
H
2.7
300
|
| Avalon GloboCare Corp |
|
3.3
|
0.4
|
L
H
0.4
0.4
|
L
 -4.8%
H
0.4
0.4
|
L
 -24.5%
H
0.3
0.6
|
L
 -37.5%
H
0.3
1.6
|
L
 -89.3%
H
0.3
4.7
|
L
 -78.7%
H
0.2
11.7
|
L
 -95.7%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
104.4
|
1.7
|
L
H
1.7
1.8
|
L
 8.8%
H
1.6
1.9
|
L
 10.2%
H
1.5
1.9
|
L
 -68.7%
H
1.1
5.7
|
L
 -19.9%
H
1.1
6.2
|
L
 -83.8%
H
1.1
12.0
|
L
 -86.1%
H
1.1
13.2
|
L
 -72.1%
H
1.1
16.7
|
| Alector Inc |
|
232.2
|
2.1
|
L
 -13.9%
H
2.1
2.3
|
L
 -11.0%
H
2.1
2.7
|
L
 -13.2%
H
2.1
2.7
|
L
 7.1%
H
1.8
2.7
|
L
 101.9%
H
1.0
3.4
|
L
 -73.5%
H
0.9
9.1
|
L
 -87.2%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
786.7
|
2.3
|
L
 0.4%
H
2.3
2.4
|
L
 6.1%
H
2.1
2.4
|
L
 -15.6%
H
1.9
4.5
|
L
 34.9%
H
1.6
4.5
|
L
 93.2%
H
0.9
4.5
|
L
 -63.9%
H
0.9
6.9
|
L
 -92.4%
H
0.9
31.8
|
L
H
0.9
55
|
| Altimmune Inc |
|
600.6
|
3.1
|
L
 1.6%
H
3.0
3.1
|
L
 9.6%
H
2.8
3.3
|
L
 -8.3%
H
2.6
3.6
|
L
 -36.6%
H
2.6
5.0
|
L
 -46.7%
H
2.6
7.7
|
L
 -37.2%
H
2.1
14.8
|
L
 -76.7%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,017.3
|
3.3
|
L
 1.9%
H
3.2
3.3
|
L
 -5.8%
H
3.2
3.6
|
L
 -8.9%
H
3.2
3.8
|
L
 -36.3%
H
3.0
5.3
|
L
 -65.3%
H
3.0
11.9
|
L
 -65.7%
H
3.0
18
|
L
H
3.0
18
|
L
H
3.0
18
|
| Kalaris Therapeutics Inc |
|
116.8
|
5.1
|
L
 -1.4%
H
5.0
5.2
|
L
 -7.0%
H
5.0
5.7
|
L
 -19.9%
H
5.0
6.7
|
L
 -39.1%
H
5.0
11.2
|
L
 32.0%
H
2.1
11.9
|
L
 16.2%
H
0.4
12.9
|
L
 -78.7%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Amgen |
|
179,118
|
331.7
|
L
 0.8%
H
328
332.3
|
L
 0.6%
H
320.5
333.0
|
L
 -5.2%
H
320.5
359.4
|
L
 -13.7%
H
320.5
391.3
|
L
 21.9%
H
261.4
391.3
|
L
 41.4%
H
211.7
391.3
|
L
 30.5%
H
198.6
391.3
|
L
 116.5%
H
133.6
391.3
|
| AnaptysBio Inc |
|
2,017.6
|
69.3
|
L
 3.5%
H
66.0
70.1
|
L
 3.9%
H
62.1
72.4
|
L
 5.8%
H
44
73.3
|
L
 39.4%
H
44
73.3
|
L
 254.1%
H
17.1
73.3
|
L
 227.6%
H
12.2
73.3
|
L
 165.0%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,862.3
|
81.9
|
L
 -2.4%
H
79.4
87.8
|
L
 1.8%
H
79.4
87.8
|
L
 3.6%
H
75.9
87.8
|
L
 0.0%
H
70.2
87.8
|
L
 14.4%
H
56.7
99.5
|
L
 92.2%
H
38.9
99.5
|
L
 112.1%
H
22.3
99.5
|
L
 76.1%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
100.6
|
3
|
L
 1.4%
H
2.9
3.0
|
L
 -4.5%
H
2.9
3.2
|
L
 9.9%
H
2.6
3.2
|
L
 1.4%
H
2.4
3.2
|
L
 14.1%
H
2.4
5.5
|
L
 -24.4%
H
2.1
5.5
|
L
 -31.4%
H
2.1
6.5
|
L
 3.8%
H
0.6
8.1
|
| AN2 Therapeutics Inc |
|
160.5
|
4.5
|
L
 -3.0%
H
4.5
4.8
|
L
 -4.7%
H
4.5
5.2
|
L
 33.5%
H
2.9
5.2
|
L
 309.2%
H
1
6.9
|
L
 265.6%
H
1
6.9
|
L
 -20.4%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
2.7
|
0.5
|
L
 -4%
H
0.5
0.5
|
L
 -4%
H
0.5
0.5
|
L
 -22.6%
H
0.5
0.8
|
L
 -48.9%
H
0.5
1.0
|
L
 -96.2%
H
0.5
12.8
|
L
 -100.0%
H
0.5
27900
|
L
 -100.0%
H
0.5
121500
|
L
 -100.0%
H
0.5
2167200
|
| Aptevo Therapeutics Inc |
|
5.9
|
5.0
|
L
 2.3%
H
4.8
5.1
|
L
 1.0%
H
4.3
5.6
|
L
 16.1%
H
4.2
5.7
|
L
 -25.8%
H
3.8
7.7
|
L
 -96.2%
H
3.8
258.1
|
L
 -100.0%
H
3.8
1078387.2
|
L
 -100.0%
H
3.8
18613900.8
|
L
H
3.8
68020444.8
|
| AquaBounty Tech Inc |
|
4.8
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 1.1%
H
0.9
1.0
|
L
 1.1%
H
0.9
1.2
|
L
 14.6%
H
0.8
1.2
|
L
 36.2%
H
0.6
3.0
|
L
 -91.3%
H
0.5
10.8
|
L
 -99.1%
H
0.5
130.6
|
L
H
0.5
610
|
| Arvinas Inc |
|
652.3
|
10.1
|
L
 -0.8%
H
10.0
10.3
|
L
 -3.8%
H
9.8
11
|
L
 -9.8%
H
9.7
11.5
|
L
 -25%
H
9.7
14.5
|
L
 48.5%
H
5.9
14.5
|
L
 -59.0%
H
5.9
53.1
|
L
 -84.1%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
10,352.3
|
72.7
|
L
 -6.8%
H
72.6
77.9
|
L
 -2.8%
H
72.6
79.5
|
L
 12.9%
H
63.3
79.5
|
L
 12.7%
H
54.0
79.5
|
L
 448.6%
H
12.9
79.5
|
L
 79.7%
H
9.6
79.5
|
L
 9.5%
H
9.6
93.7
|
L
 1200.4%
H
1.2
93.7
|
| LeonaBio Inc |
|
191.0
|
10.0
|
L
 1.8%
H
9.1
10.5
|
L
 13.8%
H
8.8
10.5
|
L
 4.8%
H
7.8
10.7
|
L
 119.2%
H
4.2
14.2
|
L
 276.0%
H
2.5
14.2
|
L
 -64.9%
H
2.2
43.0
|
L
 -94.6%
H
2.2
236.4
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
2,096.2
|
15.2
|
L
 0.6%
H
14.8
15.5
|
L
 -0.8%
H
14.4
16.3
|
L
 -4.2%
H
14.4
16.9
|
L
 5.5%
H
13.5
16.9
|
L
 87.8%
H
7.3
16.9
|
L
 36.1%
H
4.7
16.9
|
L
 50.2%
H
4.1
34.0
|
L
 511.6%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
926.5
|
8.4
|
L
 2.4%
H
8.1
8.5
|
L
 19.8%
H
6.9
9.5
|
L
 24.1%
H
6.6
9.5
|
L
 50%
H
4.9
9.5
|
L
 44.8%
H
4.3
9.5
|
L
 -15.1%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
544.3
|
29
|
L
 7.9%
H
27
30.4
|
L
 -0.2%
H
26.3
30.5
|
L
 -3.5%
H
26.3
31.5
|
L
 19%
H
16.8
36.0
|
L
 38.0%
H
14.4
36.0
|
L
 240.4%
H
1.4
61.1
|
L
 -71.9%
H
1.4
132
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,491.2
|
25.8
|
L
 6.6%
H
23.8
26.6
|
L
 6.5%
H
23.4
26.6
|
L
 54%
H
16.3
28
|
L
 68.5%
H
12.9
28
|
L
 186.8%
H
6.6
28
|
L
 -96.6%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
298.4
|
3.2
|
L
 3.2%
H
3.1
3.2
|
L
 -3.0%
H
3.1
3.5
|
L
 5.9%
H
2.9
3.8
|
L
 -21.5%
H
2.6
5.2
|
L
 -62.4%
H
2.6
14.0
|
L
 -61.7%
H
2.6
14.4
|
L
 -71.5%
H
2.6
31.5
|
L
 -33.1%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
11,186.3
|
217.4
|
L
 -1.3%
H
216.8
223.4
|
L
 5.3%
H
208.5
234.3
|
L
 25.5%
H
172.0
234.3
|
L
 19.1%
H
152.3
234.3
|
L
 99.7%
H
96.1
234.3
|
L
 179.7%
H
55.0
234.3
|
L
 281.6%
H
19.4
234.3
|
L
 1811.9%
H
1.9
234.3
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.0
|
L
 1%
H
1.0
1.1
|
L
H
1.0
1.1
|
L
 -11.4%
H
1.0
1.2
|
L
 2.0%
H
0.9
1.4
|
L
 -41.3%
H
0.5
2.6
|
L
 -55.7%
H
0.5
2.8
|
L
 -91.3%
H
0.5
12.9
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
7.2
|
6.3
|
L
 -5.0%
H
6.1
6.6
|
L
 14.3%
H
5.2
6.6
|
L
 61.1%
H
3.8
6.6
|
L
 -33.5%
H
3.3
11.2
|
L
 -88.3%
H
3.3
56.8
|
L
 -95.7%
H
3.3
219.8
|
L
 -99.6%
H
3.3
1592
|
L
 -100.0%
H
3.3
17759.8
|
| Autolus Therapeutics PLC (ADR) |
|
417.8
|
1.6
|
L
 -2.5%
H
1.6
1.6
|
L
 6.8%
H
1.5
1.8
|
L
 5.4%
H
1.4
1.8
|
L
 10.6%
H
1.2
1.9
|
L
 16.3%
H
1.2
2.7
|
L
 -16.5%
H
1.1
7.5
|
L
 -70.8%
H
1.1
8.2
|
L
H
1.1
53.2
|
| BridgeBio Pharma Inc |
|
13,126.9
|
67.4
|
L
 -0.1%
H
66
69.1
|
L
 -1.7%
H
66
70.4
|
L
 -9.1%
H
66
84.8
|
L
 -1.0%
H
62.8
84.9
|
L
 93.4%
H
31.8
84.9
|
L
 398.4%
H
12.8
84.9
|
L
 40.3%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
8.0
|
4.8
|
L
 11.3%
H
4.4
5.2
|
L
 13.4%
H
4.1
5.2
|
L
 9.0%
H
3.9
6.1
|
L
 -54.1%
H
3.9
13.3
|
L
 -79.5%
H
3.9
71.5
|
L
 -97.0%
H
3.9
203.4
|
L
 -99.8%
H
3.9
2591.5
|
L
H
3.9
3831.5
|
| BioCardia Inc |
|
12.1
|
1.1
|
L
 1.8%
H
1.0
1.2
|
L
H
1.0
1.2
|
L
 -8.3%
H
1.0
1.3
|
L
 -11.2%
H
1.0
1.4
|
L
 -61.1%
H
1
2.9
|
L
 -96.4%
H
1
43.8
|
L
 -97.9%
H
1
76.5
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
2,190.9
|
8.6
|
L
 -3.2%
H
8.6
9.0
|
L
 -6.2%
H
7.8
9.4
|
L
 -11.9%
H
7.8
10.0
|
L
 35.1%
H
6.3
10.3
|
L
 -13.1%
H
6
11.3
|
L
 1.5%
H
4.0
11.3
|
L
 -34.3%
H
4.0
20.0
|
L
 203.5%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
30.4
|
4.2
|
L
 2.2%
H
4.1
4.2
|
L
 0.2%
H
4.0
4.3
|
L
 -5.4%
H
3.7
4.7
|
L
 0.2%
H
3.6
4.7
|
L
 -98.7%
H
3.6
372
|
L
 -100.0%
H
3.6
11275.5
|
L
 -99.9%
H
3.6
18526.5
|
L
 -100.0%
H
3.6
83250
|
| Black Diamond Therapeutics Inc |
|
171.1
|
3.0
|
L
 9.9%
H
2.7
3.2
|
L
 15%
H
2.4
3.2
|
L
 19.6%
H
2.4
3.4
|
L
 32.3%
H
1.9
3.4
|
L
 76.9%
H
1.6
4.9
|
L
 55.7%
H
1.2
7.7
|
L
 -88.3%
H
1.2
28.4
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,337.4
|
32.3
|
L
 2.7%
H
30.9
32.5
|
L
 5.3%
H
28.5
32.5
|
L
 27.0%
H
25.2
32.5
|
L
 21.9%
H
21.6
34.2
|
L
 87.4%
H
15.4
36.4
|
L
 -3.1%
H
13.5
49.5
|
L
 -54.4%
H
13.5
138.5
|
L
H
13
138.5
|
| Biogen |
|
28,560.4
|
193.5
|
L
 1.1%
H
189.5
195.2
|
L
 3.4%
H
185.4
195.2
|
L
 7.5%
H
171.2
196.0
|
L
 -3.8%
H
168.6
201
|
L
 63.4%
H
118.1
202.4
|
L
 -38.5%
H
110.0
319.8
|
L
 -29.4%
H
110.0
468.6
|
L
 -20.3%
H
110.0
468.6
|
| BioVie Inc |
|
11.1
|
1.5
|
L
 -4.6%
H
1.4
1.6
|
L
 -12.5%
H
1.4
1.8
|
L
 -1.3%
H
1.4
1.8
|
L
 30.1%
H
1.1
1.8
|
L
 -88.1%
H
1.1
12.3
|
L
 -99.8%
H
1.1
869
|
L
 -99.9%
H
1.1
1910
|
L
 -99.9%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
10,449.0
|
54.1
|
L
 -0.1%
H
53.5
54.6
|
L
H
52.7
57.4
|
L
 -5.5%
H
52.5
57.4
|
L
 -7%
H
52.5
66.3
|
L
 -9.6%
H
50.8
66.3
|
L
 -43.7%
H
50.8
99.6
|
L
 -30.5%
H
50.8
117.8
|
L
 -33.1%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
14.3
|
1.3
|
L
 -3.0%
H
1.3
1.4
|
L
 9.3%
H
1.2
1.4
|
L
 9.3%
H
1.1
1.4
|
L
 12.2%
H
1.1
1.5
|
L
 -66.5%
H
1.1
5.5
|
L
 -82.2%
H
0.1
11.6
|
L
 -97.6%
H
0.1
91.2
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
420.7
|
12.3
|
L
 1.2%
H
11.8
12.7
|
L
 2.8%
H
11.4
12.7
|
L
 11.0%
H
10.6
14.3
|
L
 1.3%
H
9.9
14.3
|
L
 -10.6%
H
9.9
17.2
|
L
 228.3%
H
1.9
17.2
|
L
 -82.9%
H
1.9
99.6
|
L
 -97.2%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
9.8
|
1.2
|
L
 -1.6%
H
1.2
1.2
|
L
 -7.7%
H
1.2
1.3
|
L
 -9.1%
H
1.2
1.4
|
L
 -26.4%
H
1.1
1.7
|
L
 -15.5%
H
1.1
3.4
|
L
 -99.2%
H
1.1
200
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
33.0
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 1.7%
H
1.2
1.4
|
L
 10.9%
H
1.0
1.4
|
L
 -18.7%
H
1.0
1.8
|
L
 -22.8%
H
1.0
8.1
|
L
 -95.4%
H
0.2
29.6
|
L
 -96.0%
H
0.2
39
|
L
H
0.2
71.5
|
| Bicycle Therapeutics PLC (ADR) |
|
335.8
|
4.8
|
L
 -1.6%
H
4.8
4.9
|
L
 0.2%
H
4.8
5.2
|
L
 -3.4%
H
4.5
5.4
|
L
 -15.0%
H
4.2
6.0
|
L
 -41.2%
H
4.2
9.4
|
L
 -77.7%
H
4.2
28.9
|
L
 -84.9%
H
4.2
62.1
|
L
H
4.2
62.1
|
| BioNTech SE (ADR) |
|
23,801.5
|
94.1
|
L
 1.2%
H
92.5
96.0
|
L
 -3.5%
H
90.8
100.2
|
L
 2.2%
H
90.1
113.3
|
L
 -11.7%
H
79.5
113.3
|
L
 -0.7%
H
79.5
124
|
L
 -12.9%
H
76.5
131.5
|
L
 -48.8%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
632.6
|
3.9
|
L
 -3%
H
3.8
4.0
|
L
 32.0%
H
3.2
4.2
|
L
 25.6%
H
2.7
4.2
|
L
 54.6%
H
2.4
4.2
|
L
 220.7%
H
1.2
4.2
|
L
 -66.8%
H
1.0
26.4
|
L
 -59.5%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
9.9
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 6.8%
H
0.6
0.7
|
L
 1.6%
H
0.5
0.7
|
L
 5%
H
0.5
0.9
|
L
 -69.4%
H
0.5
7.2
|
L
 -80.6%
H
0.5
8.6
|
L
 -99.0%
H
0.5
98.8
|
L
H
0.5
530.3
|
| Tvardi Therapeutics Inc |
|
39.2
|
4.2
|
L
 -0.7%
H
4.1
4.3
|
L
 33.1%
H
3.1
4.3
|
L
 37.1%
H
2.8
4.3
|
L
 12.4%
H
2.8
4.3
|
L
 -84.0%
H
2.8
43.7
|
L
 -97.3%
H
2.8
168.1
|
L
 -99.1%
H
2.8
681.5
|
L
 -97.9%
H
2.8
1067.3
|
| Crescent Biopharma Inc |
|
-
|
18.8
|
L
 4.2%
H
18.0
19.5
|
L
 3.8%
H
16.4
19.7
|
L
 2.4%
H
14.9
27.4
|
L
 97.3%
H
8.7
27.4
|
L
 65.3%
H
7.6
27.4
|
L
 495.6%
H
3.2
27.4
|
L
 70.4%
H
0.9
27.4
|
L
 -61.5%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
325.0
|
3.0
|
L
 -1.0%
H
2.9
3.1
|
L
 1.0%
H
2.8
3.2
|
L
 1.7%
H
2.5
3.2
|
L
 62.1%
H
1.7
3.8
|
L
 91.6%
H
1.2
3.8
|
L
 -8.7%
H
1.1
11.9
|
L
 -91.4%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
274.2
|
2.9
|
L
 1.4%
H
2.8
3.0
|
L
 7.0%
H
2.6
3.0
|
L
 26.6%
H
2.3
3.2
|
L
 73.7%
H
1.6
3.2
|
L
 124.8%
H
1.3
3.2
|
L
 332.8%
H
0.5
3.2
|
L
 -61.8%
H
0.5
9.2
|
L
 -55.1%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
107.9
|
1.2
|
L
 4.3%
H
1.2
1.2
|
L
 -5.5%
H
1.1
1.3
|
L
 37.5%
H
0.9
1.4
|
L
 14.2%
H
0.6
1.4
|
L
 266.7%
H
0.2
3.8
|
L
 -24.8%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Co-Diagnostics Inc |
|
9.1
|
2.5
|
L
 31.1%
H
1.9
2.8
|
L
 63.2%
H
1.5
2.8
|
L
 82.0%
H
1.4
2.8
|
L
 7.2%
H
1.4
4.0
|
L
 -76.2%
H
1.4
46.5
|
L
 -93.9%
H
1.4
66.9
|
L
 -99.0%
H
1.4
354.6
|
L
H
1.4
929.7
|
| Z Squared Inc |
|
640.8
|
12.5
|
L
 -4.0%
H
12.4
13.3
|
L
 -13.8%
H
12.4
15.1
|
L
 14.8%
H
9
18.8
|
L
 10.6%
H
9
18.8
|
L
 42.2%
H
6.8
21.4
|
L
 -59.8%
H
2.3
43.8
|
L
 25.9%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,936.0
|
34.7
|
L
 -0.1%
H
34.5
35.4
|
L
 -5.2%
H
34.5
37.5
|
L
 -6.0%
H
34.5
38.0
|
L
 -6.3%
H
32.7
40.5
|
L
 597.6%
H
4.6
43.7
|
L
 193.4%
H
3.7
43.7
|
L
 318.1%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Caribou Biosciences Inc |
|
186.0
|
1.9
|
L
 3.2%
H
1.9
2.0
|
L
 3.7%
H
1.8
2.0
|
L
 -0.5%
H
1.8
2.4
|
L
 23.6%
H
1.5
2.4
|
L
 145.6%
H
0.8
3.5
|
L
 -54.9%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
147.4
|
1.3
|
L
 1.5%
H
1.3
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 2.3%
H
1.3
1.7
|
L
 32%
H
0.9
1.7
|
L
 15.8%
H
0.9
1.7
|
L
 131.6%
H
0.6
3.1
|
L
 -59.6%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
22.4
|
0.6
|
L
 -3.5%
H
0.6
0.6
|
L
 -5.1%
H
0.6
0.6
|
L
 1.8%
H
0.5
0.8
|
L
 -45.6%
H
0.5
1.2
|
L
 -73.3%
H
0.5
3.1
|
L
 -96.5%
H
0.5
19.6
|
L
 -99.7%
H
0.5
348
|
L
 -99.7%
H
0.5
372
|
| CorMedix Inc |
|
621.3
|
7.9
|
L
H
7.8
8.2
|
L
 1.7%
H
7.6
8.2
|
L
 9.5%
H
7.1
8.2
|
L
 3.0%
H
6.1
8.2
|
L
 -34.2%
H
6.1
17.4
|
L
 50.9%
H
2.6
17.4
|
L
 -6.9%
H
2.6
17.4
|
L
 -52%
H
0.9
18.8
|
| CRISPR Therapeutics AG |
|
5,288.3
|
54.8
|
L
 4.6%
H
52.6
55.9
|
L
 6.2%
H
49.4
55.9
|
L
 5.9%
H
48.8
59.4
|
L
 12.5%
H
44.1
61.8
|
L
 51.7%
H
34.9
78.5
|
L
 -2.0%
H
30.0
91.1
|
L
 -49.1%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
83.6
|
6.0
|
L
 0.5%
H
5.8
6.3
|
L
 0.5%
H
5.8
6.3
|
L
 -0.2%
H
5.7
6.3
|
L
 -8.1%
H
5.5
6.9
|
L
 1.7%
H
5.5
9.6
|
L
 30.0%
H
3.6
12.0
|
L
 -40.6%
H
3.6
12.0
|
L
 48.6%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
113.9
|
35
|
L
 -2.0%
H
34.0
37.0
|
L
 15.1%
H
28
41.4
|
L
 325.8%
H
6.3
41.4
|
L
 264.6%
H
5.0
41.4
|
L
 51.9%
H
5.0
41.4
|
L
 -76.2%
H
5.0
153.6
|
L
 -89.6%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
14.7
|
6.1
|
L
 1.2%
H
5.8
6.5
|
L
 -4.1%
H
5.7
7
|
L
 25.6%
H
4.5
7.3
|
L
 6.8%
H
4.2
9.0
|
L
 -60.7%
H
4.2
16.3
|
L
 328.9%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
12.7
|
1.8
|
L
 1.7%
H
1.7
1.8
|
L
 9.9%
H
1.6
1.8
|
L
 3.5%
H
1.5
1.8
|
L
 15.7%
H
1.4
2.2
|
L
 -64.0%
H
1.4
5.9
|
L
 -71.3%
H
1.4
10.2
|
L
 -97.8%
H
1.4
111.7
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,337.1
|
9.9
|
L
 5.5%
H
9.3
10.0
|
L
 10.0%
H
9.0
10.0
|
L
 73.3%
H
5.5
10.2
|
L
 60.1%
H
4.9
10.2
|
L
 163.6%
H
2.3
10.2
|
L
 17.1%
H
2.3
12.8
|
L
 -70.9%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Denali Therapeutics Inc |
|
3,661.8
|
19.6
|
L
 -0.5%
H
19.4
20.5
|
L
 7.2%
H
18.1
20.5
|
L
H
18.1
21.8
|
L
 -6.9%
H
17.9
23.5
|
L
 36.0%
H
12.6
23.8
|
L
 -26.1%
H
10.6
33.3
|
L
 -63.9%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
82.3
|
3.6
|
L
 10.6%
H
3.3
3.7
|
L
 21.3%
H
3.0
3.7
|
L
 26.4%
H
2.7
3.7
|
L
 -2.4%
H
2.7
3.7
|
L
 -31.6%
H
2.7
8.4
|
L
 23.8%
H
0.8
13.6
|
L
 -76.5%
H
0.8
20.6
|
L
 -97.2%
H
0.8
308.4
|
| DarioHealth Corp |
|
57.0
|
7.8
|
L
 -3.8%
H
7.4
8.2
|
L
 7.0%
H
7.2
8.3
|
L
 14.5%
H
6.4
8.3
|
L
 -21.5%
H
6.2
12.2
|
L
 -44.2%
H
5.9
17.7
|
L
 -89.4%
H
5.9
91.6
|
L
 -97.9%
H
5.9
476
|
L
 -99.6%
H
5.9
2360.0
|
| Bright Minds Biosciences Inc |
|
836.8
|
85.5
|
L
 -3.7%
H
85.4
90
|
L
 -1.7%
H
81.3
90.1
|
L
 3.3%
H
79.9
92.4
|
L
 12.5%
H
66.2
92.4
|
L
 166.7%
H
23.2
123.8
|
L
 2750%
H
0.9
123.8
|
L
 267.9%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
888.1
|
14.2
|
L
 0.9%
H
14.0
14.6
|
L
 6.9%
H
13.0
14.7
|
L
 12.2%
H
11.9
17.3
|
L
 38.5%
H
9.7
17.3
|
L
 304.0%
H
3.1
17.3
|
L
 87.1%
H
1.9
17.3
|
L
 -49.3%
H
1.9
29.2
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
198.4
|
7.7
|
L
 2.8%
H
7.5
8.0
|
L
 5.6%
H
6.5
8.1
|
L
 28.4%
H
6.0
8.1
|
L
 102.4%
H
3.6
8.1
|
L
 49.3%
H
3.5
8.8
|
L
 804.7%
H
0.3
19.4
|
L
 -10.4%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
2,909.5
|
17.6
|
L
 0.4%
H
17.3
17.9
|
L
 1.3%
H
17.0
19.0
|
L
 -4.2%
H
17.0
21.4
|
L
 4.8%
H
14
21.4
|
L
 55.8%
H
8.1
25
|
L
 29.1%
H
6.4
47.5
|
L
 -5.9%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
304.5
|
3.1
|
L
 2.6%
H
3.0
3.2
|
L
 7.2%
H
2.9
3.3
|
L
 12.7%
H
2.7
3.7
|
L
 70.9%
H
1.7
3.7
|
L
 123.7%
H
1.3
4.5
|
L
 -67.7%
H
0.9
11.9
|
L
 -90.9%
H
0.9
73.0
|
L
 -89.7%
H
0.9
100.0
|
| Elicio Therapeutics Inc |
|
185.4
|
9.9
|
L
 -1%
H
9.9
10.5
|
L
 -7.8%
H
9.9
11.2
|
L
 -2.2%
H
9.9
13.9
|
L
 19.1%
H
8.1
14.9
|
L
 77.9%
H
5.2
14.9
|
L
 25.4%
H
3.0
24.4
|
L
 -93.0%
H
3.0
162.6
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
2,559.1
|
40.8
|
L
 1.1%
H
40.0
42.9
|
L
 -2.3%
H
39.5
43.0
|
L
 -5.1%
H
39.5
48.5
|
L
 38.5%
H
25.3
48.5
|
L
 118.7%
H
14.8
48.5
|
L
 112.9%
H
9.8
48.5
|
L
 40.5%
H
3.9
48.5
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
775.5
|
11.4
|
L
 -4.5%
H
11.3
12.2
|
L
 27.6%
H
8.9
12.5
|
L
 60.1%
H
7.1
12.5
|
L
 109.0%
H
5.1
12.5
|
L
 855.5%
H
1.1
12.5
|
L
 237.4%
H
1.1
12.5
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
185.6
|
0.8
|
L
 -3.8%
H
0.8
0.9
|
L
 -6.1%
H
0.8
0.9
|
L
 -17.2%
H
0.7
1.0
|
L
 -33.6%
H
0.7
1.3
|
L
 -26.0%
H
0.7
2.1
|
L
 -74.2%
H
0.7
4.6
|
L
 -92.3%
H
0.7
14.0
|
L
 -99.0%
H
0.7
89.6
|
| Enochian Biosciences Inc |
|
-
|
0.3
|
L
H
0.3
0.3
|
L
 3.1%
H
0.3
0.4
|
L
 -8.3%
H
0.3
0.4
|
L
 -50%
H
0.2
1.1
|
L
 3.1%
H
0.1
1.7
|
L
 -73.0%
H
0.1
2.3
|
L
 -90.9%
H
0.1
13.8
|
L
 -83.1%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
3.2
|
0.4
|
L
 -5.4%
H
0.3
0.4
|
L
 -10.3%
H
0.3
0.4
|
L
 -30%
H
0.3
0.6
|
L
 -23.9%
H
0.3
0.8
|
L
 -83.2%
H
0.3
2.8
|
L
 -89.8%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
133.4
|
2.1
|
L
 -1.4%
H
2.1
2.3
|
L
 1.4%
H
2.0
2.3
|
L
 17.2%
H
1.7
2.5
|
L
 38.8%
H
1.5
2.7
|
L
 427.5%
H
0.3
2.7
|
L
 283.6%
H
0.3
3.3
|
L
 -65.0%
H
0.3
7.8
|
L
H
0.3
27.1
|
| Edgewise Therapeutics Inc |
|
3,783.4
|
35.3
|
L
 -0.7%
H
34.7
36.2
|
L
 15.4%
H
30.5
40.0
|
L
 6.9%
H
30.1
40.0
|
L
 21.4%
H
26.8
40.0
|
L
 140.3%
H
12.2
40.0
|
L
 257.5%
H
5.1
40.0
|
L
 20.8%
H
5.1
40.0
|
L
H
5.1
40.5
|
| Evaxion Biotech A/S (ADR) |
|
36.2
|
4.3
|
L
 6.6%
H
4.0
4.5
|
L
 -3.6%
H
3.9
4.8
|
L
 6.9%
H
3.9
4.8
|
L
 29.2%
H
3.0
4.8
|
L
 199.3%
H
1.5
12.2
|
L
 -70.7%
H
0.8
18.5
|
L
 -93.5%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
277.9
|
2.4
|
L
 -1.7%
H
2.3
2.5
|
L
 56.2%
H
1.5
2.5
|
L
 102.5%
H
1.2
2.5
|
L
 109.7%
H
1.0
2.5
|
L
 132.0%
H
0.9
2.5
|
L
 -56.1%
H
0.7
8.8
|
L
 -96.9%
H
0.7
97.4
|
L
 39.8%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
491.9
|
24.0
|
L
 -8.2%
H
23.5
26.0
|
L
 -14.8%
H
23.5
30.4
|
L
 -8.6%
H
23.5
35.8
|
L
 -12.9%
H
22.0
35.8
|
L
 285.6%
H
6.2
35.8
|
L
 -9.4%
H
4.1
35.8
|
L
 -97.1%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
690.2
|
10.1
|
L
 2.1%
H
9.1
10.2
|
L
 11.6%
H
9.1
10.4
|
L
 0.4%
H
8.6
10.7
|
L
 12.8%
H
8.0
10.9
|
L
 213.0%
H
3
12.3
|
L
 -38.6%
H
2.2
36.3
|
L
 -69.1%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Foghorn Therapeutics Inc |
|
308.8
|
4.4
|
L
 5.7%
H
4.1
4.5
|
L
 -6.7%
H
4.1
4.9
|
L
 -9.2%
H
4.1
5.6
|
L
 -21.8%
H
4.1
6.0
|
L
 -2.0%
H
3.3
7.0
|
L
 -18.2%
H
2.7
10.2
|
L
 -55.0%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Frequency Therapeutics Inc |
|
-
|
12.1
|
L
 -6.5%
H
11.6
12.7
|
L
 -11.2%
H
11.6
13.8
|
L
 -10.5%
H
11.6
14.5
|
L
 -4.1%
H
9.9
15.6
|
L
 -20.3%
H
5.2
55.9
|
L
 -37.4%
H
5.2
55.9
|
L
 -97.7%
H
5.2
545
|
L
H
5.2
2918.5
|
| First Wave BioPharma Inc |
|
5.3
|
3.4
|
L
 20%
H
2.8
3.5
|
L
 35.7%
H
2.4
3.5
|
L
 64.4%
H
2
3.5
|
L
 17.5%
H
1.9
3.5
|
L
 714.3%
H
0.4
5.8
|
L
 -94.1%
H
0.4
62.4
|
L
 -100.0%
H
0.4
40741.3
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
138.2
|
2.1
|
L
 -0.5%
H
2.1
2.1
|
L
 -7.5%
H
2.0
2.4
|
L
 -5.4%
H
2.0
2.6
|
L
 -25%
H
2.0
3.5
|
L
 50%
H
1.2
7.1
|
L
 11.7%
H
0.7
7.1
|
L
 -47.5%
H
0.7
7.1
|
L
 68%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
77.6
|
1.8
|
L
 -2.7%
H
1.8
1.9
|
L
 -3.2%
H
1.8
2.0
|
L
 1.1%
H
1.7
2.2
|
L
 4%
H
1.7
3.1
|
L
 -9.9%
H
1.4
4.3
|
L
 -65.8%
H
0.9
5.5
|
L
 -82.7%
H
0.9
11
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
9.2
|
0.8
|
L
 8.3%
H
0.7
0.8
|
L
 -19.6%
H
0.7
1
|
L
 -22%
H
0.7
1.0
|
L
 -33.3%
H
0.7
1.1
|
L
 -66.1%
H
0.7
3.7
|
L
 -82.3%
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
891.7
|
1.4
|
L
 -4.8%
H
1.4
1.5
|
L
 -12.0%
H
1.4
1.7
|
L
 -18.7%
H
1.4
1.8
|
L
 -9.2%
H
1.4
2.0
|
L
 10.3%
H
1.0
2.0
|
L
 -49.5%
H
1.0
5.3
|
L
 4.5%
H
1.0
5.3
|
L
 -47.9%
H
0.8
7.0
|
| Gilead Sciences |
|
164,687.8
|
131.3
|
L
 -2.0%
H
129
133.3
|
L
 -0.2%
H
129
136.8
|
L
 -7.2%
H
127.6
143.0
|
L
 -13.9%
H
127.6
157.3
|
L
 33.8%
H
96.2
157.3
|
L
 67.1%
H
62.1
157.3
|
L
 97.4%
H
57.2
157.3
|
L
 55.1%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
316.7
|
22.9
|
L
 -3.2%
H
22.9
24.0
|
L
 -3.5%
H
21.4
24.0
|
L
 -5.5%
H
21.3
30.3
|
L
 -21.2%
H
20.5
30.3
|
L
 136.7%
H
7.8
34.1
|
L
 104.8%
H
7.6
34.1
|
L
 -32.3%
H
6.8
49.0
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,635.0
|
19.4
|
L
 -2.1%
H
19.2
20.1
|
L
 3.1%
H
18.6
20.7
|
L
 13.3%
H
16.9
21.6
|
L
 -0.8%
H
14.2
21.6
|
L
 359.5%
H
3.5
25.8
|
L
 257.1%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
4.8
|
1.7
|
L
 -5.1%
H
1.5
1.8
|
L
 44.0%
H
1.1
2
|
L
 41.5%
H
1.0
2
|
L
 -37.5%
H
1.0
2.8
|
L
 -93.1%
H
1.0
34.8
|
L
 -99.3%
H
1.0
288.4
|
L
 -99.9%
H
1.0
2812.5
|
L
 -100.0%
H
1.0
379518072.3
|
| Graphite Bio Inc |
|
585.9
|
10.1
|
L
 3.5%
H
9.6
10.1
|
L
 13.3%
H
8.9
10.1
|
L
 6.5%
H
8.7
10.4
|
L
 -29.3%
H
8.3
15.0
|
L
 -62.5%
H
8.3
50.4
|
L
 -93.6%
H
8.3
413
|
L
H
8.3
1666
|
L
H
8.3
1666
|
| Galapagos NV (ADR) |
|
1,884.0
|
28.6
|
L
 3.1%
H
27.7
29.7
|
L
 2.1%
H
27.2
29.7
|
L
 -1.0%
H
27.2
29.7
|
L
 -14.3%
H
27.2
36.2
|
L
 12.1%
H
24.7
37.8
|
L
 -31.9%
H
22.4
45.2
|
L
 -61.9%
H
22.4
81.1
|
L
 -37.6%
H
22.4
274.0
|
| Halozyme Therapeutics Inc |
|
7,596.6
|
64.1
|
L
 -1.6%
H
64
65.8
|
L
 0.3%
H
63.1
67.4
|
L
 -2%
H
62.4
70.3
|
L
 -21.1%
H
61.3
82.2
|
L
 -5.3%
H
47.5
82.2
|
L
 111.8%
H
29.9
82.2
|
L
 34.8%
H
29.9
82.2
|
L
 574.9%
H
7.7
82.2
|
| HCW Biologics Inc |
|
2.2
|
0.3
|
L
 3.1%
H
0.3
0.3
|
L
 -26.7%
H
0.3
0.5
|
L
H
0.3
0.5
|
L
 -68.3%
H
0.3
1.2
|
L
 -95.4%
H
0.3
17.8
|
L
 -99.4%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
35.5
|
3.0
|
L
 1.3%
H
2.9
3.1
|
L
 -6.5%
H
2.9
3.3
|
L
 -7.9%
H
2.9
3.8
|
L
 -27.1%
H
2.9
5.3
|
L
 127.1%
H
1.1
9.1
|
L
 -72.0%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
228.3
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 -4.7%
H
1.2
1.3
|
L
 45.8%
H
0.8
1.3
|
L
 -4.0%
H
0.7
1.3
|
L
 -44.2%
H
0.7
2.3
|
L
 -50.4%
H
0.5
3.9
|
L
 -92.7%
H
0.5
18.8
|
L
 -92.8%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
28.4
|
4.9
|
L
 -2.6%
H
4.7
5.0
|
L
 -12.1%
H
4.7
5.7
|
L
 32.6%
H
2.8
6.2
|
L
 16.2%
H
2.1
6.5
|
L
 -44.2%
H
2.1
38.3
|
L
 -93.8%
H
2.1
109.2
|
L
 -95.6%
H
2.1
146.3
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
235.3
|
1.1
|
L
 -1.9%
H
1.0
1.1
|
L
 23.3%
H
0.9
1.1
|
L
 63.1%
H
0.6
1.1
|
L
 12.8%
H
0.6
1.3
|
L
 -12.4%
H
0.6
2.9
|
L
 -78.7%
H
0.6
10.0
|
L
 -89.4%
H
0.6
17.5
|
L
H
0.6
17.5
|
| Immucell Corp |
|
72.8
|
8.1
|
L
 -5.0%
H
8.0
8.7
|
L
 -7.8%
H
8.0
9.1
|
L
 26.2%
H
6.8
9.1
|
L
 29.0%
H
6
9.1
|
L
 56.6%
H
4.5
9.1
|
L
 62.6%
H
3.3
9.1
|
L
 -19.5%
H
3.3
11.0
|
L
 24.0%
H
3.3
13.2
|
| InflaRx N.V. |
|
186.5
|
2.6
|
L
 -2.6%
H
2.4
2.8
|
L
 22.9%
H
1.9
3.0
|
L
 171.6%
H
1.0
3.0
|
L
 186.7%
H
0.8
3.0
|
L
 63.3%
H
0.7
3.0
|
L
 -37.1%
H
0.7
5.2
|
L
 -28.7%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
59.3
|
5.3
|
L
 -10.5%
H
5.3
5.9
|
L
 -6.5%
H
5.3
6.1
|
L
 15.8%
H
4.5
6.6
|
L
 -23.4%
H
3.9
7.6
|
L
 -59.2%
H
3.9
18
|
L
 -93.7%
H
3.9
89.2
|
L
 -98.1%
H
3.9
291.0
|
L
H
3.9
451.3
|
| Illumina Inc |
|
21,466.4
|
141.9
|
L
 2.3%
H
134.7
142.2
|
L
 4.5%
H
134.0
143.0
|
L
 10.8%
H
118.3
143.0
|
L
 18.5%
H
112.7
143.0
|
L
 78.3%
H
75.3
155.5
|
L
 -27.5%
H
68.7
213.9
|
L
 -63.0%
H
68.7
526
|
L
 0.8%
H
68.7
555.8
|
| Immunome Inc |
|
2,541.3
|
22.4
|
L
 1.1%
H
22.1
22.7
|
L
 -1.3%
H
21.8
24.0
|
L
 3.4%
H
21.4
24.9
|
L
 -9.8%
H
19.2
25.2
|
L
 191.1%
H
7.4
27.7
|
L
 289.6%
H
4.5
31.0
|
L
 2.1%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
10.8
|
2.7
|
L
 -0.4%
H
2.7
2.8
|
L
 -2.9%
H
2.7
3.0
|
L
 -13.1%
H
2.7
3.2
|
L
 -16.8%
H
2.5
3.6
|
L
 -78.3%
H
2.5
47.4
|
L
 -87.0%
H
2.5
54.8
|
L
 -98.9%
H
2.5
348.8
|
L
 -99.9%
H
2.5
5040
|
| Immatics N.V |
|
1,524.7
|
11.4
|
L
 2.1%
H
11.1
11.5
|
L
 5.4%
H
10.6
11.7
|
L
 8.0%
H
10.4
11.7
|
L
 18.1%
H
9.1
11.7
|
L
 162.0%
H
4.2
12.4
|
L
 15.7%
H
3.3
13.8
|
L
 -1.3%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunovant Inc |
|
5,890.2
|
28.9
|
L
 6.3%
H
27.2
29.9
|
L
 6.7%
H
26.8
29.9
|
L
 17.0%
H
24.4
30.1
|
L
 7.0%
H
22.8
30.1
|
L
 102.4%
H
13.5
30.1
|
L
 49.8%
H
12.7
45.6
|
L
 72.7%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
15.6
|
1.6
|
L
 -1.3%
H
1.6
1.7
|
L
 5.3%
H
1.5
1.7
|
L
 9.0%
H
1.3
1.7
|
L
 -20.6%
H
1.3
2.1
|
L
 829.4%
H
0.1
4.2
|
L
 -37.3%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
6,365.2
|
134.4
|
L
 7.9%
H
121.4
134.9
|
L
 4.3%
H
120.5
142.1
|
L
 100.1%
H
66.4
155.3
|
L
 60.1%
H
57.3
155.3
|
L
 1093.2%
H
10.8
155.3
|
L
 407.9%
H
10.8
155.3
|
L
 750.9%
H
7.7
155.3
|
L
H
7.7
155.3
|
| MiNK Therapeutics Inc |
|
55.0
|
11.0
|
L
 -1.3%
H
11
11.4
|
L
 -4.9%
H
11.0
12.4
|
L
 -1.0%
H
10.4
14.9
|
L
 0.6%
H
8.5
16.9
|
L
 59.5%
H
6.3
76
|
L
 -39.3%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
38.0
|
1.4
|
L
H
1.4
1.5
|
L
 -5.3%
H
1.4
1.6
|
L
 10.9%
H
1.2
1.6
|
L
 -5.3%
H
1.1
1.7
|
L
 -79.8%
H
1.1
11.6
|
L
 -82.9%
H
1.1
14.7
|
L
 -86.6%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
1,515.0
|
3.6
|
L
 2.0%
H
3.4
3.6
|
L
 6.5%
H
3.4
4.2
|
L
 4.3%
H
3.3
4.3
|
L
 43.1%
H
2.5
5.6
|
L
 14.2%
H
1.6
5.6
|
L
 -48.9%
H
1.6
18.3
|
L
 -87.3%
H
1.6
28.1
|
L
 -30.5%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
413.0
|
2.3
|
L
 -0.9%
H
2.2
2.3
|
L
 -0.9%
H
2.2
2.4
|
L
H
2.2
2.6
|
L
 34.7%
H
1.7
3.0
|
L
 340.4%
H
0.4
3.0
|
L
 -29.1%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,607.5
|
68.3
|
L
 1.1%
H
67.4
70.3
|
L
 2.0%
H
66.1
70.3
|
L
 3%
H
65.0
72.4
|
L
 -14.4%
H
40
79.8
|
L
 54.1%
H
40
99.5
|
L
 119.8%
H
25.6
99.5
|
L
 -43.0%
H
11.6
129.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
424.2
|
1.5
|
L
 4.9%
H
1.4
1.5
|
L
 -1.3%
H
1.4
1.6
|
L
 11.1%
H
1.3
1.8
|
L
 -5.7%
H
1.2
2.0
|
L
 154.2%
H
0.5
3.1
|
L
 28.2%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,504.6
|
29.6
|
L
 -3.4%
H
29.5
30.7
|
L
 5.0%
H
27.9
31.5
|
L
 -7.1%
H
27.6
32.8
|
L
 -7.5%
H
27.6
34.9
|
L
 -0.7%
H
27.4
40.7
|
L
 -50.6%
H
23.2
77.0
|
L
 -26.6%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
66.3
|
0.5
|
L
 4.7%
H
0.4
0.5
|
L
 2.3%
H
0.4
0.5
|
L
 28.6%
H
0.3
1.1
|
L
 -82.8%
H
0.3
3.0
|
L
 -75.8%
H
0.3
3.5
|
L
 -71.9%
H
0.3
3.9
|
L
 -87.2%
H
0.3
5.4
|
L
 -86.0%
H
0.3
8.0
|
| Inventiva (ADR) |
|
1,115.1
|
5.4
|
L
 0.4%
H
5.3
5.5
|
L
 8.1%
H
5.0
5.6
|
L
 1.3%
H
4.9
5.8
|
L
 -8.7%
H
4.9
7.1
|
L
 52.6%
H
2.9
8.0
|
L
 88.4%
H
1.5
8.0
|
L
 -62.7%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
888.6
|
14.2
|
L
 -2.5%
H
13.9
14.7
|
L
 -1.1%
H
13.9
14.8
|
L
 -2.4%
H
13.9
16.6
|
L
 8.5%
H
12.7
16.6
|
L
 -46.2%
H
12.1
35.3
|
L
 3.4%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
26.0
|
0.9
|
L
 2.2%
H
0.9
1.0
|
L
H
0.9
1.0
|
L
 31.0%
H
0.7
1.1
|
L
 -31.1%
H
0.6
1.5
|
L
 -79.0%
H
0.6
7.2
|
L
 -35.4%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kamada Ltd |
|
493.2
|
8.6
|
L
 3.5%
H
8.4
8.6
|
L
 4.1%
H
8.2
8.6
|
L
 0.9%
H
8.1
8.6
|
L
 4.1%
H
8.0
9.4
|
L
 22.3%
H
6.5
9.4
|
L
 73.1%
H
4.1
9.4
|
L
 39.7%
H
3.7
9.4
|
L
 109.0%
H
3.6
13.3
|
| Kodiak Sciences Inc |
|
2,536.9
|
41.0
|
L
 -6.1%
H
40.9
44.2
|
L
 -6.7%
H
40.9
46.6
|
L
 -1.9%
H
39.4
47.8
|
L
 78.0%
H
21
47.8
|
L
 925.3%
H
2.8
47.8
|
L
 742.1%
H
1.4
47.8
|
L
 -59.6%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
9,012.3
|
305.7
|
L
 3.0%
H
292
306.1
|
L
 14.9%
H
252.0
306.1
|
L
 15.7%
H
252.0
306.1
|
L
 12.1%
H
242
306.1
|
L
 122.9%
H
122.8
306.1
|
L
 248.8%
H
86.0
306.1
|
L
 331.9%
H
38.9
306.1
|
L
H
8.0
306.1
|
| TuHURA Biosciences Inc |
|
151.6
|
2.4
|
L
 -0.8%
H
2.3
2.4
|
L
 2.2%
H
2.1
2.6
|
L
 31.5%
H
1.7
3.4
|
L
 277.8%
H
0.6
3.4
|
L
 -39.4%
H
0.4
4.2
|
L
 -97.9%
H
0.2
196
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Kura Oncology Inc |
|
836.1
|
9.4
|
L
 1.1%
H
9.3
9.5
|
L
 7.4%
H
8.9
9.6
|
L
 7.2%
H
8.5
10.0
|
L
 20.3%
H
7.5
10.0
|
L
 57%
H
5.5
12.5
|
L
 -15.8%
H
5.4
24.2
|
L
 -64.0%
H
5.4
26.4
|
L
 241.3%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
7,080.7
|
86.1
|
L
 1.7%
H
83.7
86.9
|
L
 6.7%
H
79.2
86.9
|
L
 -1.2%
H
77.6
90.1
|
L
 8.2%
H
73.3
95.9
|
L
 179.8%
H
28.1
103
|
L
 210.3%
H
9.6
103
|
L
 95.4%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
53.9
|
7.3
|
L
 -1.0%
H
7.3
7.5
|
L
 -0.6%
H
7.3
7.5
|
L
 -1.2%
H
7.2
7.5
|
L
 19.1%
H
6.1
7.6
|
L
 76.9%
H
3.5
7.6
|
L
 -72.4%
H
0.7
31.3
|
L
 -87.0%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Longeveron Inc (Class A) |
|
24.6
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 -1.2%
H
0.8
0.9
|
L
 -25.7%
H
0.8
1.2
|
L
 64.7%
H
0.5
1.2
|
L
 -43.6%
H
0.5
1.8
|
L
 -97.3%
H
0.5
44
|
L
 -98.5%
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
59.9
|
5.2
|
L
 4.7%
H
4.8
5.6
|
L
 53.1%
H
3.3
5.6
|
L
 81.1%
H
2.7
5.6
|
L
 74.9%
H
2.4
5.6
|
L
 326.5%
H
0.6
6.3
|
L
 -5.0%
H
0.6
9.5
|
L
 -81.7%
H
0.6
49.5
|
L
 -27.7%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
116.2
|
1.2
|
L
 12.3%
H
1.1
1.2
|
L
 22.7%
H
1.0
1.3
|
L
 46.9%
H
0.8
1.3
|
L
 72.5%
H
0.5
1.3
|
L
 230.6%
H
0.2
3.7
|
L
 -69.5%
H
0.2
10.2
|
L
 -92.7%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
412.4
|
4.0
|
L
 -0.8%
H
3.9
4.2
|
L
 0.8%
H
3.9
4.3
|
L
 -22%
H
3.9
5.2
|
L
 17.8%
H
2.7
6.4
|
L
 77.2%
H
1.7
6.4
|
L
 -17.6%
H
1.6
13.7
|
L
 -71.4%
H
1.5
15.5
|
L
 -94.6%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
451.0
|
19.3
|
L
 -3.6%
H
19.1
20.5
|
L
 -7.2%
H
19.1
21.5
|
L
 -15.6%
H
19.1
25.3
|
L
 -14.9%
H
17.3
27.8
|
L
 125.8%
H
7.7
45
|
L
 -58.0%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
143.0
|
2.1
|
L
H
2.1
2.2
|
L
 1.4%
H
2.1
2.2
|
L
 -9.4%
H
2.0
2.7
|
L
 21.0%
H
1.7
2.9
|
L
 -16.8%
H
1.6
4.7
|
L
 85.2%
H
0.8
4.7
|
L
 -69.7%
H
0.8
9.6
|
L
 -99.5%
H
0.8
526.5
|
| Seres Therapeutics Inc |
|
74.6
|
7.7
|
L
 -0.3%
H
7.5
7.9
|
L
 1.2%
H
6.9
8.3
|
L
 -12.1%
H
6.6
9.2
|
L
 -44.8%
H
6.6
14.7
|
L
 10.6%
H
6.5
30.0
|
L
 38.5%
H
0.4
30.0
|
L
 -62.9%
H
0.4
30.0
|
L
 -68.0%
H
0.4
38.5
|
| MeiraGTx Holdings PLC |
|
909.1
|
9.8
|
L
 1.5%
H
9.6
10.0
|
L
 4.4%
H
9.0
10.1
|
L
 4.6%
H
8.8
11.9
|
L
 32.2%
H
6.6
11.9
|
L
 79.5%
H
4.6
11.9
|
L
 67.0%
H
3.5
11.9
|
L
 -29.6%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,437.0
|
29.5
|
L
 0.7%
H
28.6
30
|
L
 1.0%
H
28.0
30.9
|
L
 6.4%
H
25.2
31.5
|
L
 -0.8%
H
22.4
32.2
|
L
 89.2%
H
12.6
47.7
|
L
 82.8%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
425.9
|
63.6
|
L
 1.8%
H
61.6
65.6
|
L
 19.4%
H
51.8
66.2
|
L
 9.6%
H
50.1
66.2
|
L
 10.1%
H
50.1
66.2
|
L
 50.1%
H
28.4
105
|
L
 1171.6%
H
1.4
105
|
L
 140.8%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
24.3
|
1.5
|
L
 1.4%
H
1.4
1.5
|
L
H
1.4
1.6
|
L
H
1.4
1.8
|
L
 -11.5%
H
1.2
1.8
|
L
 14.1%
H
0.8
4.1
|
L
 -12.6%
H
0.8
9.7
|
L
 -93.8%
H
0.7
36.5
|
L
 -98.1%
H
0.7
135.5
|
| Moderna |
|
21,565.3
|
54.4
|
L
 12.0%
H
49.0
57.8
|
L
 19.8%
H
45.3
57.8
|
L
 4.3%
H
43.7
57.8
|
L
 32.5%
H
36.7
59.6
|
L
 122.9%
H
22.3
59.6
|
L
 -58.7%
H
22.3
170.5
|
L
 -66.7%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
710.2
|
4.9
|
L
 23.1%
H
4.4
5.0
|
L
 30.0%
H
3.6
5.0
|
L
 56.0%
H
3.0
5.0
|
L
 54.5%
H
2.8
5.0
|
L
 134.3%
H
2.0
5.0
|
L
 -65.1%
H
1.7
16.6
|
L
 -86.9%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
90.0
|
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 -4.6%
H
0.8
0.9
|
L
 12%
H
0.7
0.9
|
L
 3.7%
H
0.6
0.9
|
L
 -65.4%
H
0.6
2.5
|
L
 -82.3%
H
0.6
5.5
|
L
 -85.6%
H
0.6
17.4
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
4.5
|
0.4
|
L
 -2.7%
H
0.3
0.4
|
L
 -12.2%
H
0.3
0.4
|
L
 -29.4%
H
0.3
0.6
|
L
 -61.7%
H
0.3
1.0
|
L
 -85.9%
H
0.3
2.6
|
L
 -99.8%
H
0.3
240
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
1,905.6
|
14.7
|
L
 -0.4%
H
14.5
14.8
|
L
 -6.4%
H
14.5
16.1
|
L
 5.9%
H
14.1
16.9
|
L
 -7.6%
H
13.3
18.4
|
L
 29.2%
H
9.9
21.5
|
L
 332.3%
H
1.0
22
|
L
 111.2%
H
1.0
22
|
L
 98.7%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
153.4
|
4.1
|
L
H
4.1
4.1
|
L
 -3.3%
H
4.1
4.4
|
L
 -3.3%
H
4
4.5
|
L
 -12.8%
H
3.7
5.4
|
L
 3.5%
H
3.4
5.4
|
L
 -39.2%
H
3.3
12.7
|
L
 -81.5%
H
3.3
32.0
|
L
 -85.0%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
39.9
|
0.3
|
L
 4.2%
H
0.2
0.3
|
L
 -3.9%
H
0.2
0.3
|
L
 -21.9%
H
0.2
0.4
|
L
 -40.5%
H
0.2
0.5
|
L
 -89.7%
H
0.2
3.1
|
L
 -78.6%
H
0.2
5.0
|
L
 -92.6%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
340.6
|
2.7
|
L
 -6.9%
H
2.7
2.9
|
L
 -0.7%
H
2.7
3.1
|
L
 -14.4%
H
2.4
3.3
|
L
 32.0%
H
2.0
4.3
|
L
 272.2%
H
0.6
4.3
|
L
 12.6%
H
0.6
4.7
|
L
 -73.3%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Nkarta Inc |
|
227.4
|
3.2
|
L
 1.3%
H
3.1
3.3
|
L
 8.9%
H
2.9
3.4
|
L
 38.1%
H
2.1
3.7
|
L
 57.9%
H
2.0
3.7
|
L
 63.6%
H
1.6
3.7
|
L
 -30.7%
H
1.3
16.2
|
L
 -88.5%
H
1.3
40.6
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
30.8
|
L
 -1.5%
H
29.6
31.8
|
L
 14.6%
H
26.2
33.5
|
L
 42.4%
H
19.1
33.5
|
L
 78.6%
H
16.2
33.5
|
L
 71.1%
H
14.7
37.3
|
L
 74.9%
H
12.2
37.3
|
L
 -86.7%
H
7.5
234.6
|
L
 -80.0%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
8.8
|
L
 1.3%
H
8.7
8.8
|
L
 -0.7%
H
8.5
8.9
|
L
 15.9%
H
7.5
9.3
|
L
 9.7%
H
7.0
9.3
|
L
 24.0%
H
6.2
9.3
|
L
 1126.4%
H
0.0
9.3
|
L
 -62.3%
H
0.0
31
|
L
H
0.0
1010
|
| MetaVia Inc |
|
5.6
|
1.1
|
L
 -18.1%
H
1
1.3
|
L
 -24.3%
H
1
1.5
|
L
 -11.4%
H
1
1.7
|
L
 -40.1%
H
1
2.0
|
L
 -86.0%
H
1
19.0
|
L
 -98.0%
H
1
74.3
|
L
 -100.0%
H
1
17344.8
|
L
H
1
1424940
|
| Intellia Therapeutics Inc |
|
1,675.7
|
14.1
|
L
 2.8%
H
13.7
14.6
|
L
 6.3%
H
13.1
14.6
|
L
 1.6%
H
11.8
17.0
|
L
 14.7%
H
11.2
17.0
|
L
 70.2%
H
6.8
28.3
|
L
 -67.4%
H
5.9
47.5
|
L
 -79.2%
H
5.9
202.7
|
L
 -36.2%
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
8,282.4
|
105.3
|
L
 2.8%
H
102.3
107.5
|
L
 6.3%
H
98.3
107.5
|
L
 0.2%
H
97.8
109.5
|
L
 1.6%
H
93.9
109.5
|
L
 47.0%
H
68.6
113.0
|
L
 178.8%
H
37.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,662.5
|
10.1
|
L
 9.5%
H
9.3
10.8
|
L
 25.8%
H
7.8
10.8
|
L
 20.1%
H
7.7
10.8
|
L
 22.6%
H
7.6
12.0
|
L
 51.8%
H
5.8
12.0
|
L
 35.7%
H
3.5
23.9
|
L
 -94.3%
H
3.5
277.8
|
L
 -89.0%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
8.8
|
2.1
|
L
 1.0%
H
2.1
2.2
|
L
 -6.2%
H
2.1
2.3
|
L
 11.1%
H
1.9
2.3
|
L
 -5.0%
H
1.3
2.3
|
L
 -100.0%
H
1.3
8000
|
L
 -100.0%
H
1.3
950000
|
L
 -100.0%
H
1.3
3600000
|
L
H
1.3
32000000
|
| Insight Molecular Diagnostics Inc |
|
161.8
|
5.0
|
L
 1.0%
H
4.6
5.1
|
L
 19.9%
H
4.2
5.4
|
L
 65.9%
H
2.6
5.4
|
L
 -31.6%
H
2.4
7.5
|
L
 76.4%
H
2.3
8.5
|
L
 -6.5%
H
1.9
8.5
|
L
 -94.1%
H
1.9
125
|
L
 -95.0%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
85.5
|
1.6
|
L
 0.6%
H
1.6
1.7
|
L
 -1.8%
H
1.6
1.7
|
L
 2.5%
H
1.5
1.7
|
L
 -15.1%
H
1.4
2.3
|
L
 10.1%
H
1.3
3.4
|
L
 -23.5%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
103.4
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 2.3%
H
0.9
1.0
|
L
 -2.2%
H
0.8
1.2
|
L
H
0.8
1.2
|
L
 64.8%
H
0.3
1.5
|
L
 -48.0%
H
0.3
3.4
|
L
 -68.9%
H
0.3
3.4
|
L
 -82.6%
H
0.3
8.5
|
| Traws Pharma Inc |
|
33.0
|
2.2
|
L
 28.2%
H
1.8
2.4
|
L
 46.3%
H
1.5
2.4
|
L
 39.7%
H
1
2.4
|
L
 11.2%
H
1
2.5
|
L
 55.7%
H
1.0
3.3
|
L
 -93.9%
H
1.0
35.5
|
L
 -99.0%
H
1.0
412.5
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
4.0
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 -3.5%
H
1.4
1.5
|
L
 -12.0%
H
1.4
1.9
|
L
 -39.0%
H
1.3
2.3
|
L
 -29.8%
H
1.3
5.3
|
L
 -94.0%
H
0.3
24.6
|
L
 -98.4%
H
0.3
135
|
L
 -99.8%
H
0.3
1197.6
|
| Passage Bio Inc |
|
13.5
|
4.2
|
L
 3.2%
H
3.9
4.3
|
L
 -15.3%
H
3.9
5.0
|
L
 -54.7%
H
3.9
12.1
|
L
 -55.7%
H
3.9
12.1
|
L
 -39.3%
H
3.9
20
|
L
 -79.2%
H
3.9
35.8
|
L
 -98.8%
H
3.9
352.4
|
L
H
3.9
764.6
|
| Vaxcyte Inc |
|
7,654.0
|
53.0
|
L
 3.0%
H
50.8
53.4
|
L
 -6.9%
H
48.5
59.7
|
L
 -11.8%
H
48.5
63.3
|
L
 -5.6%
H
48.5
65
|
L
 68.6%
H
28.6
65
|
L
 4.2%
H
27.7
121.1
|
L
 200.5%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
121.7
|
1.8
|
L
 -1.7%
H
1.7
1.9
|
L
 0.6%
H
1.7
1.9
|
L
 6.0%
H
1.5
1.9
|
L
 -60.7%
H
1.3
7.1
|
L
 14.3%
H
1.0
7.8
|
L
 -88.3%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,500.9
|
4.2
|
L
 1.5%
H
4.1
4.2
|
L
 3.2%
H
4.0
4.4
|
L
 2.2%
H
3.8
4.4
|
L
 -1.9%
H
3.0
5.5
|
L
 211.9%
H
1.3
5.5
|
L
 236.8%
H
0.7
5.5
|
L
 -35.6%
H
0.7
8.7
|
L
 -83.9%
H
0.7
32.9
|
| Phio Pharma Corp |
|
12.4
|
1.1
|
L
 -6.1%
H
1.0
1.2
|
L
 -6.1%
H
1.0
1.2
|
L
 -17.7%
H
1.0
1.3
|
L
 16.3%
H
0.9
1.9
|
L
 -40.6%
H
0.8
4.2
|
L
 -97.0%
H
0.6
61.7
|
L
 -99.6%
H
0.6
283.0
|
L
 -100.0%
H
0.6
194238
|
| Pliant Therapeutics Inc |
|
75.5
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 1.7%
H
1.2
1.3
|
L
 -10.3%
H
1.2
1.4
|
L
 7.0%
H
1.1
1.4
|
L
 -16.4%
H
1.1
2.0
|
L
 -94.5%
H
1.1
24.7
|
L
 -96.3%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
37.5
|
3.5
|
L
 4.2%
H
3.4
3.5
|
L
 3.9%
H
3.2
3.5
|
L
 3.6%
H
3.2
3.9
|
L
 0.3%
H
3.0
3.9
|
L
 -34.2%
H
2.8
6.1
|
L
 -52.7%
H
0.7
8.6
|
L
 -89.0%
H
0.7
36.4
|
L
 -97.3%
H
0.7
169.6
|
| Prelude Therapeutics Inc |
|
387.1
|
4.9
|
L
 -5.6%
H
4.8
5.3
|
L
 3.4%
H
4.3
5.3
|
L
 15.2%
H
3.8
5.5
|
L
 124.0%
H
2.0
5.5
|
L
 492.7%
H
0.8
5.5
|
L
 -23.7%
H
0.6
6.9
|
L
 -88.3%
H
0.6
45.3
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
568.5
|
3.2
|
L
 2.9%
H
3.1
3.4
|
L
 -5.9%
H
3.1
3.6
|
L
 -9.3%
H
3.1
4.0
|
L
 -10.1%
H
3.0
4.8
|
L
 143.2%
H
1.1
6.9
|
L
 -77.3%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
264.1
|
1.9
|
L
 -1.1%
H
1.9
1.9
|
L
 -3.6%
H
1.8
2.0
|
L
 0.5%
H
1.8
2.2
|
L
 -0.5%
H
1.6
2.6
|
L
 165.7%
H
0.5
7.1
|
L
 -80.2%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
580.6
|
10.7
|
L
 2%
H
10.6
11.8
|
L
 0.9%
H
10.4
11.8
|
L
 0.8%
H
10.2
11.8
|
L
 20.4%
H
8.2
11.8
|
L
 51.1%
H
4.3
11.8
|
L
 -86.0%
H
4.3
78.5
|
L
 -56.4%
H
4.3
79.8
|
L
 -72.0%
H
4.3
79.8
|
| Alpha Compute Corp |
|
5.6
|
0.2
|
L
 -7.7%
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -25%
H
0.2
0.4
|
L
 -55.6%
H
0.2
0.6
|
L
 -97.3%
H
0.2
13.8
|
L
 -99.6%
H
0.2
88
|
L
 -100.0%
H
0.2
899.5
|
L
 -99.9%
H
0.2
1310
|
| Protagonist Therapeutics Inc |
|
6,390.0
|
99.4
|
L
 0.5%
H
97
100.2
|
L
 1.0%
H
97
105.0
|
L
 -2.7%
H
95.4
107
|
L
 17.6%
H
77
107.8
|
L
 126.2%
H
42.9
107.8
|
L
 298.6%
H
13.7
107.8
|
L
 240.5%
H
6.9
107.8
|
L
H
4.5
107.8
|
| PureTech Health Plc ADR |
|
417.2
|
17.1
|
L
 1%
H
16.7
17.4
|
L
 -5.5%
H
16.6
18.1
|
L
 9.1%
H
16.1
19.3
|
L
 -5.3%
H
14.5
19.3
|
L
 -0.6%
H
14.5
19.9
|
L
 -40.7%
H
13.3
34
|
L
 -69.8%
H
13.3
59.9
|
L
H
13.3
65.9
|
| Quince Therapeutics Inc |
|
20.9
|
1.3
|
L
 -1.5%
H
1.2
1.3
|
L
 -3.8%
H
1.2
1.3
|
L
 -30.1%
H
1.1
1.6
|
L
 -7.9%
H
0.8
9.8
|
L
 -87.6%
H
0.8
45.5
|
L
 -92.1%
H
0.8
45.5
|
L
 -99.7%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
1,744.4
|
27.7
|
L
 14.5%
H
23.5
29.5
|
L
 44.6%
H
19.4
29.5
|
L
 74.1%
H
13.2
29.5
|
L
 7.8%
H
8.7
29.5
|
L
 125.8%
H
8.7
71.5
|
L
 27.9%
H
3.7
71.5
|
L
 -15.0%
H
3.7
71.5
|
L
 129.2%
H
3.7
82.5
|
| Rain Oncology Inc |
|
46.2
|
1.3
|
L
 -13.0%
H
1.3
1.5
|
L
 -41.5%
H
1.3
2.2
|
L
 -52.3%
H
1.3
2.7
|
L
 -42.0%
H
1.3
3.8
|
L
 -81.2%
H
1.3
9.2
|
L
 -86.2%
H
0.8
10.5
|
L
 -93.1%
H
0.8
22.2
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
96.8
|
1.0
|
L
 4.3%
H
1.0
1.0
|
L
 3.2%
H
0.9
1
|
L
 16.9%
H
0.7
1.1
|
L
 -20.5%
H
0.7
1.4
|
L
 24.4%
H
0.4
3.9
|
L
 -77.3%
H
0.4
8.8
|
L
 -99.5%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
407.0
|
3.6
|
L
 -1.1%
H
3.5
4.0
|
L
 2.0%
H
3.5
4.0
|
L
 0.8%
H
3.3
4.1
|
L
 14.9%
H
3.1
5.5
|
L
 -48.4%
H
2.2
7.4
|
L
 -83.0%
H
2.2
32.5
|
L
 -91.7%
H
2.2
49.7
|
L
 -91.3%
H
2.2
67.5
|
| Replimune Grp Inc |
|
336.1
|
4.1
|
L
 21.9%
H
3.3
4.2
|
L
 62.8%
H
2.5
4.2
|
L
 -30.8%
H
1.5
6.7
|
L
 -47.5%
H
1.5
9.1
|
L
 -47.6%
H
1.5
13.2
|
L
 -77.5%
H
1.5
24.8
|
L
 -88.6%
H
1.5
40.2
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
3.6
|
1.0
|
L
 -5.9%
H
1.0
1.0
|
L
 -14.3%
H
1.0
1.1
|
L
 -20.7%
H
1.0
1.3
|
L
 -41.8%
H
1.0
1.6
|
L
 -97.4%
H
1.0
40.1
|
L
 -100.0%
H
1.0
7488
|
L
 -100.0%
H
1.0
2276064
|
L
H
1.0
2276064
|
| Relay Therapeutics Inc |
|
2,444.6
|
12.8
|
L
 2%
H
12.4
12.9
|
L
 0.3%
H
11.8
13.4
|
L
 -12.1%
H
11.8
17.3
|
L
 43.1%
H
8.4
17.3
|
L
 325.3%
H
2.7
17.3
|
L
 17.9%
H
1.8
17.3
|
L
 -56.7%
H
1.8
38.6
|
L
H
1.8
64.4
|
| TransCode Therapeutics Inc |
|
6.7
|
7.3
|
L
 -4.3%
H
7.3
8
|
L
 -6.5%
H
7.3
8.3
|
L
 -12.4%
H
7.3
10.3
|
L
 -17.9%
H
7.3
11.1
|
L
 -25.3%
H
6.1
21.0
|
L
 -100.0%
H
6.1
286070.4
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,762.1
|
3.3
|
L
 1.5%
H
3.2
3.4
|
L
 -2.1%
H
3.1
3.6
|
L
 -2.1%
H
3.1
3.9
|
L
 -16.6%
H
2.8
4.1
|
L
 -24.4%
H
2.8
7.2
|
L
 -40.7%
H
2.8
16.7
|
L
 -88.0%
H
2.8
42.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
6,453.7
|
94.2
|
L
 -2.1%
H
93.2
96.8
|
L
 15.1%
H
81.1
99
|
L
 10.2%
H
79.4
99
|
L
 -9.1%
H
74.5
106.3
|
L
 55.1%
H
55.3
122.2
|
L
 464.9%
H
15.5
122.2
|
L
 325.7%
H
3.0
122.2
|
L
H
3.0
122.2
|
| SAB Biotherapeutics Inc |
|
288.8
|
4.1
|
L
 0.5%
H
3.8
4.6
|
L
 18.4%
H
3.5
4.6
|
L
 10.2%
H
3.4
4.6
|
L
 -1.4%
H
3.4
5.2
|
L
 139.0%
H
1.6
6.6
|
L
 319.4%
H
0.4
6.6
|
L
 -58.5%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
947.7
|
3.5
|
L
 0.3%
H
3.4
3.6
|
L
 7.3%
H
3.3
3.7
|
L
 9.4%
H
3.0
4.1
|
L
 -10.7%
H
2.7
4.5
|
L
 93.9%
H
1.6
6.6
|
L
 -36.6%
H
1.3
12
|
L
 -80.7%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
62.8
|
1.3
|
L
 -4.4%
H
1.3
1.4
|
L
 -13.9%
H
1.3
1.5
|
L
 -23.5%
H
1.3
1.8
|
L
 -36.0%
H
1.3
2.5
|
L
 -23.5%
H
1.3
5.0
|
L
 -94.4%
H
1.2
42.2
|
L
 -96.9%
H
1.2
146.2
|
L
 -92.3%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
103.0
|
1.9
|
L
 -0.5%
H
1.9
1.9
|
L
 -7.9%
H
1.8
2.1
|
L
 10.7%
H
1.7
2.1
|
L
 4.5%
H
1.7
2.2
|
L
 -1.1%
H
1.7
2.4
|
L
 -47.5%
H
1.5
5.7
|
L
 -95.1%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,339.5
|
8.7
|
L
 6%
H
8.2
8.7
|
L
 39.1%
H
6.2
8.7
|
L
 40.7%
H
5.8
8.7
|
L
 33.3%
H
5.6
9.3
|
L
 -15.7%
H
5.6
15.6
|
L
 -15.7%
H
5.6
15.6
|
L
 -15.7%
H
5.6
15.6
|
L
 -15.7%
H
5.6
15.6
|
| Solid Biosciences Inc |
|
715.5
|
7.3
|
L
 2.8%
H
7.0
7.3
|
L
 2.0%
H
6.8
7.5
|
L
 -9.4%
H
6.8
8.9
|
L
 11.5%
H
5.2
8.9
|
L
 162.5%
H
2.4
8.9
|
L
 34.4%
H
1.8
15.1
|
L
 -89.7%
H
1.8
73.7
|
L
H
1.8
822.6
|
| Summit Therapeutics Inc |
|
14,033.0
|
18.1
|
L
 5.4%
H
17.1
18.2
|
L
 12.2%
H
16
18.2
|
L
 -3.9%
H
15.1
29.2
|
L
 20.6%
H
14.6
29.2
|
L
 -26.7%
H
13.8
31.0
|
L
 832.0%
H
1.5
36.9
|
L
 210.7%
H
0.7
36.9
|
L
 111.0%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,904.2
|
21.5
|
L
 4.6%
H
20.5
21.9
|
L
 12.5%
H
19.1
21.9
|
L
 -12.5%
H
19
25.2
|
L
 2.3%
H
19
25.6
|
L
 95.2%
H
8.6
25.6
|
L
 5.9%
H
8.6
25.6
|
L
 34.0%
H
8.6
29.9
|
L
 48.3%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
31.4
|
23.4
|
L
 -1.5%
H
22.8
25.2
|
L
 -13.2%
H
22.8
33
|
L
 -26.2%
H
22.8
33.8
|
L
 164.1%
H
8.7
36.8
|
L
 210.3%
H
5.3
36.8
|
L
 -25.9%
H
5
38.8
|
L
 -90.1%
H
5
302.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
30.8
|
1.0
|
L
 1.0%
H
1.0
1.0
|
L
 -2.9%
H
0.9
1.1
|
L
 16.5%
H
0.8
1.2
|
L
 6.5%
H
0.8
1.2
|
L
 -70.1%
H
0.8
3.9
|
L
 -90.7%
H
0.8
16.9
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
152.7
|
56.5
|
L
 -0.1%
H
56.2
57.5
|
L
 -1.4%
H
55.6
60.3
|
L
 -11.2%
H
51.4
74
|
L
 -22.0%
H
48.1
86.9
|
L
 931.0%
H
4.4
240
|
L
 -66.8%
H
4.3
446.3
|
L
 -95.1%
H
4.3
1214.3
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
148.2
|
2.6
|
L
 2.0%
H
2.5
2.6
|
L
 3.2%
H
2.4
2.6
|
L
 -5.9%
H
2.4
2.9
|
L
 5.8%
H
2.1
2.9
|
L
 341.4%
H
0.6
3.2
|
L
 34.7%
H
0.5
3.2
|
L
 -80.9%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
6,158.9
|
48.4
|
L
 4.2%
H
45.9
48.5
|
L
 4.4%
H
45
49.9
|
L
 -3.2%
H
45
51.0
|
L
 1.6%
H
38.8
51.6
|
L
 56.2%
H
27.1
51.6
|
L
 502.6%
H
5.6
51.6
|
L
 57.7%
H
4.3
51.6
|
L
H
4.3
70
|
| Surrozen Inc |
|
336.2
|
29.0
|
L
 -5.8%
H
28.6
31.0
|
L
 -13.8%
H
28.6
35
|
L
 11.7%
H
25.1
35
|
L
 27.0%
H
21.6
35
|
L
 233.3%
H
5.9
35
|
L
 4808.5%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
2,074.2
|
32.9
|
L
 0.3%
H
31.3
33.3
|
L
 -0.6%
H
31.3
35.2
|
L
 -5.7%
H
31.3
37.4
|
L
 1.5%
H
29.9
40.2
|
L
 263.4%
H
8.7
40.2
|
L
 173.2%
H
3.4
40.2
|
L
 1.3%
H
3.4
41.6
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
525.3
|
6.9
|
L
 9.4%
H
6.3
6.9
|
L
 -2%
H
6.0
7.4
|
L
 -2.4%
H
6.0
8.3
|
L
 81.7%
H
3.7
8.3
|
L
 628.7%
H
0.7
8.3
|
L
 153.7%
H
0.7
11.8
|
L
 -76.8%
H
0.7
31.2
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
4.1
|
1.5
|
L
 -2.5%
H
1.5
1.6
|
L
 -7.2%
H
1.5
1.7
|
L
 -14.9%
H
1.5
2.4
|
L
 -63.0%
H
1.3
4.2
|
L
 -83.0%
H
1.3
14.7
|
L
H
1.3
2076
|
L
H
1.3
2076
|
L
H
1.3
2076
|
| Alaunos Therapeutics Inc |
|
6.2
|
2.6
|
L
 -3.4%
H
2.6
2.6
|
L
 -1.2%
H
2.5
2.9
|
L
 -11.3%
H
2.4
3.1
|
L
 -1.9%
H
2.4
3.7
|
L
 -14.3%
H
1.7
6.2
|
L
 330%
H
0.0
6.2
|
L
 -19.4%
H
0.0
6.2
|
L
 -63.1%
H
0.0
8.7
|
| Tscan Therapeutics Inc |
|
82.3
|
1.3
|
L
 4.1%
H
1.2
1.3
|
L
 3.3%
H
1.2
1.3
|
L
 18.9%
H
1
1.5
|
L
 22.3%
H
0.9
1.5
|
L
 -8.7%
H
0.9
2.6
|
L
 -44%
H
0.9
9.7
|
L
H
0.9
14.7
|
L
H
0.9
14.7
|
| Bio-Techne |
|
7,571.7
|
48.4
|
L
 -5.0%
H
47.9
50.5
|
L
 -12.1%
H
45.1
57
|
L
 -12.4%
H
45.1
62.5
|
L
 -27.6%
H
45.1
66.5
|
L
 -2.9%
H
45.1
72.2
|
L
 -41.2%
H
45.1
89.9
|
L
 -54.3%
H
45.1
136.0
|
L
 91.7%
H
23.9
136.0
|
| Instil Bio Inc |
|
55.3
|
8.2
|
L
 1.6%
H
8.1
8.2
|
L
 3.3%
H
7.7
8.3
|
L
 -4.5%
H
7.6
9
|
L
 5.2%
H
7.5
9.8
|
L
 -37.4%
H
5.7
42.8
|
L
 1117.9%
H
0.3
92
|
L
 -56.9%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
3,320.5
|
23.0
|
L
 -2.0%
H
22.9
23.9
|
L
 9.7%
H
21.0
24.3
|
L
 14.8%
H
19.7
28.4
|
L
 84.0%
H
10.8
28.4
|
L
 1992.7%
H
1.1
28.4
|
L
 569.2%
H
1.0
28.4
|
L
H
1.0
28.4
|
L
H
1.0
28.4
|
| Entrada Therapeutics Inc |
|
286.2
|
6.8
|
L
 -0.2%
H
6.0
6.9
|
L
 -52.8%
H
5.7
16.5
|
L
 -52.2%
H
5.7
16.5
|
L
 -35.5%
H
5.7
16.5
|
L
 -20.7%
H
4.9
16.5
|
L
 -41.0%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
2,058.7
|
14.5
|
L
 3.2%
H
14.4
15.4
|
L
 4.5%
H
13.4
15.4
|
L
 10.9%
H
12.8
16.1
|
L
 26.5%
H
9.8
16.1
|
L
 119.7%
H
5.4
16.1
|
L
 360.3%
H
1.0
16.1
|
L
 590.5%
H
0.5
16.1
|
L
H
0.5
16.1
|
| Taysha Gene Therapies Inc |
|
1,956.9
|
6.8
|
L
 2.1%
H
6.6
7.0
|
L
 7.6%
H
6.3
7.3
|
L
 49.7%
H
4.3
7.3
|
L
 47.7%
H
4.0
7.3
|
L
 224.3%
H
2.1
7.3
|
L
 859.2%
H
0.5
7.3
|
L
 -67.9%
H
0.5
27.0
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
3,540.1
|
56.9
|
L
 -2.9%
H
56
59
|
L
 -5.9%
H
55.7
60.6
|
L
 11.1%
H
47.1
66.1
|
L
 15.5%
H
41.5
66.1
|
L
 74.3%
H
23.3
66.1
|
L
 324.3%
H
11.8
66.1
|
L
 -51.3%
H
11.5
140.0
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
2,771.1
|
21.6
|
L
 -3.7%
H
19.8
22.0
|
L
 -3.7%
H
19.8
23.2
|
L
 -6.2%
H
19.5
26.4
|
L
 16.1%
H
15.9
26.4
|
L
 150.3%
H
8.1
26.4
|
L
 -60.4%
H
6.8
63.6
|
L
 -85.2%
H
6.8
209.0
|
L
H
6.8
209.0
|
| UroGen Pharma Ltd |
|
1,432.4
|
29.4
|
L
 10.6%
H
27.0
30.5
|
L
 27.8%
H
22.7
30.5
|
L
 53.9%
H
18.7
30.5
|
L
 37.7%
H
16.5
30.5
|
L
 175.5%
H
3.4
30.5
|
L
 136.9%
H
3.4
30.5
|
L
 61.4%
H
3.4
30.5
|
L
H
3.4
69.6
|
| Vera Therapeutics Inc (Class A) |
|
2,586.7
|
36.2
|
L
 0.9%
H
35.8
36.9
|
L
 2.8%
H
34.0
36.9
|
L
 -10.3%
H
34.0
47
|
L
 -16.8%
H
34.0
47
|
L
 64.3%
H
18.8
56.1
|
L
 378.7%
H
7.1
56.1
|
L
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,538.1
|
9.1
|
L
 -1.6%
H
9.1
9.5
|
L
 -8.8%
H
9.1
10.5
|
L
 -4.2%
H
9.1
11.7
|
L
 26.8%
H
7.0
11.7
|
L
 68.6%
H
4.2
11.7
|
L
 -62.2%
H
4.2
27.5
|
L
 -78.8%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
917.9
|
16.9
|
L
 5.4%
H
15.9
17.3
|
L
 22.3%
H
13.7
17.3
|
L
 7.6%
H
13.7
17.3
|
L
 28.7%
H
11.7
19.7
|
L
 10487.5%
H
0.1
50.0
|
L
 309.2%
H
0.1
50.0
|
L
 -30.9%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
484.8
|
4.9
|
L
 -13.6%
H
4.8
5.5
|
L
 -16.3%
H
4.8
6.1
|
L
 -10.3%
H
4.8
6.8
|
L
 -26.7%
H
4.8
6.8
|
L
 -29.5%
H
4.0
11.2
|
L
 -3.0%
H
2.1
15.2
|
L
 -85.7%
H
2.1
59.2
|
L
 -71.3%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
24.2
|
0.6
|
L
 3.4%
H
0.6
0.6
|
L
 -3.2%
H
0.6
0.7
|
L
 10.9%
H
0.5
0.7
|
L
 8.9%
H
0.4
0.7
|
L
 -72.9%
H
0.4
5.1
|
L
 -83.9%
H
0.4
24.7
|
L
 -99.2%
H
0.4
106.5
|
L
 -99.7%
H
0.4
210
|
| Voyager Therapeutics Inc |
|
241.0
|
4.1
|
L
 2.3%
H
3.9
4.3
|
L
 7.7%
H
3.8
4.3
|
L
 3.3%
H
3.6
4.3
|
L
 10.1%
H
3.3
5.5
|
L
 18.1%
H
2.6
5.6
|
L
 -51.3%
H
2.6
14.3
|
L
 -6.0%
H
2.5
14.3
|
L
 -66.7%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
530.1
|
5.6
|
L
 0.5%
H
5.5
5.6
|
L
 4.5%
H
5.1
5.8
|
L
 -10.6%
H
5.1
6.4
|
L
 -41.1%
H
5.1
12.2
|
L
 -12.4%
H
5.1
12.3
|
L
 -54.3%
H
3.6
17.1
|
L
 -81.1%
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
1,381.4
|
7.2
|
L
 -0.8%
H
7.1
7.3
|
L
 -1.9%
H
7.0
7.6
|
L
 1.1%
H
6.9
7.7
|
L
 -46.6%
H
5.0
15.5
|
L
 9.8%
H
5.0
21.7
|
L
 80.4%
H
3.2
21.7
|
L
 18.1%
H
1.2
21.7
|
L
 -52.8%
H
1.2
56
|
| XBiotech Inc |
|
75.0
|
2.5
|
L
 -1.6%
H
2.5
2.5
|
L
 -3.5%
H
2.5
2.6
|
L
 5.1%
H
2.3
2.7
|
L
 3.8%
H
2.2
2.7
|
L
 -13.7%
H
2.1
3.6
|
L
 -25.2%
H
2.1
10.0
|
L
 -85.6%
H
2.1
18.5
|
L
 -79.8%
H
2.1
26.4
|
| Exicure Inc |
|
21.5
|
3.4
|
L
 0.6%
H
3.2
3.4
|
L
 4.0%
H
3.2
3.5
|
L
 -16.4%
H
3.2
4.2
|
L
 -16.4%
H
3.2
5.1
|
L
 -70.4%
H
3.1
11.9
|
L
 -37.6%
H
0.3
36
|
L
 -98.8%
H
0.3
297
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,159.9
|
6.5
|
L
 -1.5%
H
6.3
6.6
|
L
 4.0%
H
6.2
7
|
L
 10.3%
H
5.8
7
|
L
 -6.9%
H
5.3
7.3
|
L
 26.6%
H
4.3
10.1
|
L
 172.1%
H
1.5
10.1
|
L
 100.9%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
417.8
|
4.4
|
L
 3.3%
H
4.3
4.6
|
L
 5.7%
H
4.1
4.6
|
L
 9.4%
H
4.0
4.7
|
L
 24.4%
H
2.8
4.8
|
L
 34.7%
H
1.4
4.8
|
L
 171.8%
H
0.2
6.6
|
L
 -45.0%
H
0.2
9.9
|
L
H
0.2
172.2
|
| Xencor Inc |
|
953.5
|
12.9
|
L
 4.5%
H
12
13.2
|
L
 1.3%
H
12
13.8
|
L
 5.0%
H
11.5
13.8
|
L
 10.8%
H
10.6
14.5
|
L
 46.3%
H
6.9
18.7
|
L
 -53.0%
H
6.9
29.0
|
L
 -67.5%
H
6.9
43.6
|
L
 13.5%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
2.8
|
0.6
|
L
 -11.3%
H
0.5
0.7
|
L
 -54.0%
H
0.5
1.0
|
L
 -70.6%
H
0.5
2.6
|
L
 -89.2%
H
0.5
6.9
|
L
 -99.9%
H
0.5
434.7
|
L
 -100.0%
H
0.5
8164546.2
|
L
 -100.0%
H
0.5
58684500
|
L
 -100.0%
H
0.5
67850460
|
| Zentalis Pharma Inc |
|
313.9
|
4.4
|
L
 4.3%
H
4.2
4.4
|
L
 7.8%
H
3.9
4.4
|
L
 59.8%
H
2.9
7.0
|
L
 84.5%
H
2.1
7.0
|
L
 250%
H
1.1
7.0
|
L
 -79.8%
H
1.0
31.5
|
L
 -92.5%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
537.5
|
4.8
|
L
 5.5%
H
4.4
4.8
|
L
 -8.1%
H
4.4
5.5
|
L
 -16.0%
H
4.4
5.9
|
L
 -20.3%
H
4.4
7.4
|
L
 280.2%
H
1.0
7.4
|
L
 -5.9%
H
1.0
14
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,089.8
|
18.6
|
L
 -5.9%
H
18.3
19.5
|
L
 -13.7%
H
18.3
21.6
|
L
 -13.0%
H
18.3
25.3
|
L
 3.3%
H
17.1
25.3
|
L
 -36.2%
H
16.0
44.3
|
L
 -49.7%
H
13.5
44.3
|
L
 -88.2%
H
13.5
181.9
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
6,255.5
|
83.0
|
L
 1.5%
H
82.1
84.2
|
L
 2.8%
H
80.5
85.5
|
L
 -0.1%
H
80.5
95.3
|
L
 33.4%
H
60.4
95.3
|
L
 119.6%
H
34.3
95.3
|
L
H
14.2
95.3
|
L
H
14.2
95.3
|
L
H
14.2
95.3
|
| Intensity Therapeutics Inc |
|
13.5
|
5.1
|
L
 -0.4%
H
5.0
5.2
|
L
 -1.9%
H
5.0
5.4
|
L
 -7.5%
H
5.0
5.8
|
L
 -41.6%
H
5.0
9.8
|
L
 -64.2%
H
4.6
43.5
|
L
 -94.9%
H
4.6
286
|
L
 -94.9%
H
4.6
286
|
L
 -94.9%
H
4.6
286
|
| Renovaro Biosciences Inc |
|
12.0
|
0.3
|
L
H
0.3
0.3
|
L
 3.1%
H
0.3
0.4
|
L
 -8.3%
H
0.3
0.4
|
L
 -50%
H
0.2
1.1
|
L
 -89.3%
H
0.2
5.5
|
L
H
0.2
52.5
|
L
H
0.2
52.5
|
L
H
0.2
52.5
|
| Elutia Inc (Class A) |
|
47.0
|
1.0
|
L
 1%
H
1.0
1.1
|
L
H
1.0
1.1
|
L
 -11.4%
H
1.0
1.2
|
L
 2.0%
H
0.9
1.4
|
L
 -49.3%
H
0.5
2.6
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Canton Strategic Holdings Inc |
|
171.1
|
3.0
|
L
 1.3%
H
2.9
3.1
|
L
 -6.5%
H
2.9
3.3
|
L
 -7.9%
H
2.9
3.8
|
L
 -27.1%
H
2.9
5.3
|
L
 102.7%
H
1.1
9.1
|
L
 -98.1%
H
0.3
187.1
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Gyre Therapeutics Inc |
|
724.5
|
7.5
|
L
 5.7%
H
7.2
7.5
|
L
 -4.2%
H
7.0
8.1
|
L
 5.4%
H
7.0
8.2
|
L
 -5.2%
H
6.6
9.1
|
L
 -21.2%
H
6.6
11.8
|
L
 -0.4%
H
5.6
130.5
|
L
 -0.4%
H
5.6
130.5
|
L
 -0.4%
H
5.6
130.5
|
| Lexeo Therapeutics Inc |
|
457.8
|
5.8
|
L
 0.2%
H
5.7
6.0
|
L
 1.0%
H
5.7
6.3
|
L
 -9.5%
H
5.5
7.0
|
L
 -18.6%
H
5.0
8
|
L
 94.3%
H
2.4
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Korro Bio Inc |
|
173.8
|
12.1
|
L
 -6.5%
H
11.6
12.7
|
L
 -11.2%
H
11.6
13.8
|
L
 -10.5%
H
11.6
14.5
|
L
 -4.1%
H
9.9
15.6
|
L
 -21.8%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Cartesian Therapeutics Inc |
|
254.2
|
8.7
|
L
 6%
H
8.2
8.7
|
L
 39.1%
H
6.2
8.7
|
L
 40.7%
H
5.8
8.7
|
L
 33.3%
H
5.6
9.3
|
L
 -17.0%
H
5.6
15.6
|
L
 -99.2%
H
5.6
1278
|
L
 -99.7%
H
5.6
4752
|
L
H
5.6
25199.6
|
| Elevai Labs Inc |
|
8.8
|
2.0
|
L
 -8.3%
H
2.0
2.1
|
L
 -21.1%
H
2.0
2.5
|
L
 -56%
H
2.0
7
|
L
 -81.3%
H
1.6
14
|
L
 -99%
H
1.6
309.1
|
L
H
1.6
499117.9
|
L
H
1.6
499117.9
|
L
H
1.6
499117.9
|
| Spyre Therapeutics Inc |
|
6,516.6
|
75.0
|
L
 2.7%
H
72.4
75.9
|
L
 8.1%
H
67.2
75.9
|
L
 44.4%
H
50.9
76
|
L
 113.7%
H
32.4
76
|
L
 483.5%
H
12.9
76
|
L
H
8.8
76
|
L
H
8.8
76
|
L
H
8.8
76
|
| Neurogene Inc |
|
480.7
|
30.8
|
L
 -1.5%
H
29.6
31.8
|
L
 14.6%
H
26.2
33.5
|
L
 42.4%
H
19.1
33.5
|
L
 78.6%
H
16.2
33.5
|
L
 105.2%
H
13.7
37.3
|
L
 117.1%
H
6.9
74.5
|
L
 117.1%
H
6.9
74.5
|
L
 117.1%
H
6.9
74.5
|
| Cg Oncology Inc |
|
6,127.3
|
69.6
|
L
 0.6%
H
68.6
70.3
|
L
 5.1%
H
65.6
70.3
|
L
 1.1%
H
63.0
73.6
|
L
 38.2%
H
49.3
73.6
|
L
 188.5%
H
23.3
73.6
|
L
H
14.8
73.6
|
L
H
14.8
73.6
|
L
H
14.8
73.6
|
| FibroBiologics Inc |
|
6.0
|
1.2
|
L
 -6.5%
H
1.1
1.3
|
L
 -20.6%
H
1.1
1.4
|
L
 -17.1%
H
1.1
1.8
|
L
 -77.0%
H
1.0
9.6
|
L
 -93.1%
H
1.0
22.6
|
L
H
1.0
1100
|
L
H
1.0
1100
|
L
H
1.0
1100
|
| Kyverna Therapeutics Inc |
|
566.0
|
9.4
|
L
 0.5%
H
9.0
9.4
|
L
 5.4%
H
8.7
9.5
|
L
 1.4%
H
8.3
11.6
|
L
 17.9%
H
7.2
11.6
|
L
 339.0%
H
2.1
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
53.1
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 1.4%
H
1.4
1.5
|
L
 1.4%
H
1.3
1.6
|
L
 -8.4%
H
1.3
1.8
|
L
 -11.3%
H
1.3
4.0
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
| Tevogen Bio Holdings Inc |
|
31.3
|
7.5
|
L
H
7
7.5
|
L
 12.3%
H
6.5
7.5
|
L
 28.7%
H
5.3
9.4
|
L
 -45.6%
H
4.1
15.4
|
L
 -86.3%
H
4.1
75.5
|
L
H
4.1
1054.5
|
L
H
4.1
1054.5
|
L
H
4.1
1054.5
|
| NeOnc Tech Holdings Inc |
|
137.8
|
5.5
|
L
 -16.0%
H
5.4
6.8
|
L
 34.2%
H
4
6.8
|
L
 1.5%
H
3.9
6.8
|
L
 -44.2%
H
3.9
11.4
|
L
 -17.4%
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
| LENZ Therapeutics Inc |
|
315.4
|
10.1
|
L
 3.5%
H
9.6
10.1
|
L
 13.3%
H
8.9
10.1
|
L
 6.5%
H
8.7
10.4
|
L
 -29.3%
H
8.3
15.0
|
L
 -61.1%
H
8.3
50.4
|
L
 -59.6%
H
8.3
50.4
|
L
 -59.6%
H
8.3
50.4
|
L
 -59.6%
H
8.3
50.4
|
| Boundless Bio Inc |
|
32.3
|
1.4
|
L
 -5.9%
H
1.4
1.6
|
L
 -8.3%
H
1.4
1.7
|
L
 25.2%
H
1.1
1.7
|
L
 24.1%
H
1.1
1.7
|
L
 -4%
H
1.0
1.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
543.2
|
14.5
|
L
 -0.7%
H
14.3
14.9
|
L
 10.1%
H
12.8
15.7
|
L
 13.6%
H
11.8
15.7
|
L
 -3.1%
H
11.8
16.3
|
L
 267.9%
H
3.4
16.3
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
458.2
|
7.5
|
L
 -0.3%
H
7.3
7.6
|
L
 -5.6%
H
7.1
8.0
|
L
 8.3%
H
6.8
8.1
|
L
 -10.8%
H
6.5
8.8
|
L
 96.1%
H
3.7
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
21.2
|
3.4
|
L
 20%
H
2.8
3.5
|
L
 35.7%
H
2.4
3.5
|
L
 64.4%
H
2
3.5
|
L
 17.5%
H
1.9
3.5
|
L
 185%
H
1.1
5.8
|
L
 -59.0%
H
0.6
9.5
|
L
 -59.0%
H
0.6
9.5
|
L
 -59.0%
H
0.6
9.5
|
| Artiva Biotherapeutics Inc |
|
269.2
|
10.9
|
L
 -13.0%
H
10.2
12.7
|
L
 0.8%
H
10.2
13
|
L
 75.9%
H
6.1
14.5
|
L
 170.2%
H
3.6
14.5
|
L
 399.5%
H
1.5
14.5
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
1,907.8
|
41.0
|
L
 18.0%
H
34.6
41.3
|
L
 37.5%
H
28.8
41.3
|
L
 29.4%
H
27.6
41.3
|
L
 8.7%
H
26.1
41.3
|
L
 249.8%
H
9.4
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
| BioAge Labs Inc |
|
798.7
|
18.0
|
L
 1.0%
H
17.5
18.2
|
L
 7.2%
H
16.1
18.8
|
L
 -0.3%
H
15.8
20.4
|
L
 -13.2%
H
15.5
23
|
L
 337.7%
H
3.7
24
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| OnKure Therapeutics Inc (Class A) |
|
157.9
|
3.9
|
L
 -1.3%
H
3.9
4.0
|
L
 -17.3%
H
3.9
5.0
|
L
 -10.7%
H
3.9
5.4
|
L
 56.4%
H
2.4
5.4
|
L
 95.5%
H
1.7
5.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
4.5
|
L
 2.8%
H
4.1
4.5
|
L
 10.1%
H
3.8
4.5
|
L
 -2.6%
H
3.8
5.1
|
L
 16.2%
H
3.5
7.8
|
L
 93.9%
H
1.3
7.8
|
L
 93.9%
H
1.3
7.8
|
L
 93.9%
H
1.3
7.8
|
L
 93.9%
H
1.3
7.8
|
| Upstream Bio Inc |
|
494.7
|
9.1
|
L
 1.2%
H
8.8
9.4
|
L
 -3.3%
H
8.7
9.6
|
L
 -7.6%
H
8.7
10.7
|
L
 -65.3%
H
7.3
28.6
|
L
 2.8%
H
7.3
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Medicus Pharma Ltd |
|
18.8
|
0.3
|
L
 9.7%
H
0.3
0.4
|
L
 21.4%
H
0.3
0.4
|
L
 -27.7%
H
0.3
0.5
|
L
 -69.4%
H
0.3
1.7
|
L
 -95.0%
H
0.3
8.9
|
L
 -94.9%
H
0.3
8.9
|
L
 -94.9%
H
0.3
8.9
|
L
 -94.9%
H
0.3
8.9
|
| Telix Pharma Ltd (ADR) |
|
3,618.1
|
10.7
|
L
 0.2%
H
10.6
10.9
|
L
 -5.2%
H
10.6
11.3
|
L
 9.2%
H
9.7
11.5
|
L
 50.4%
H
6.3
11.5
|
L
 -37.4%
H
6.3
18.5
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
1,587.1
|
121.3
|
L
 7.1%
H
113.6
121.7
|
L
 -4.4%
H
111.1
132.5
|
L
 -1.5%
H
111.1
138.6
|
L
 47.6%
H
76.5
151.2
|
L
 426.4%
H
20.2
151.2
|
L
 791.8%
H
11.2
151.2
|
L
 791.8%
H
11.2
151.2
|
L
 791.8%
H
11.2
151.2
|
| Sionna Therapeutics Inc |
|
1,996.6
|
44.2
|
L
 2.1%
H
43.4
45.1
|
L
 13.0%
H
38.6
45.8
|
L
 19.7%
H
35.1
46.5
|
L
 22.5%
H
32.6
46.5
|
L
 251.9%
H
11.8
46.5
|
L
H
7.3
46.5
|
L
H
7.3
46.5
|
L
H
7.3
46.5
|
| Zenas Biopharma Inc |
|
1,225.0
|
19.6
|
L
 1.9%
H
19.0
20
|
L
 1.5%
H
18.9
22.2
|
L
 -5.9%
H
17.4
22.2
|
L
 -9.9%
H
17.2
29.6
|
L
 87.6%
H
8.9
44.6
|
L
 87.6%
H
8.9
44.6
|
L
 87.6%
H
8.9
44.6
|
L
 87.6%
H
8.9
44.6
|
| Propanc Biopharma Inc |
|
2.0
|
0.1
|
L
H
0.1
0.1
|
L
 -10%
H
0.1
0.1
|
L
 -30.8%
H
0.1
0.2
|
L
 -52.6%
H
0.1
0.2
|
L
 -96.9%
H
0.1
9.4
|
L
 -96.9%
H
0.1
9.4
|
L
 -96.9%
H
0.1
9.4
|
L
 -96.9%
H
0.1
9.4
|
| SpyGlass Pharma Inc |
|
782.5
|
23.4
|
L
 -7.8%
H
23.4
25.8
|
L
 -2.4%
H
23.4
25.8
|
L
 5.4%
H
20.4
25.9
|
L
 -11.3%
H
20.2
30.6
|
L
 -11.3%
H
20.2
30.6
|
L
 -11.3%
H
20.2
30.6
|
L
 -11.3%
H
20.2
30.6
|
L
 -11.3%
H
20.2
30.6
|
| AgomAb Therapeutics NV ADR |
|
597.4
|
12.1
|
L
 6.2%
H
11.2
12.8
|
L
 8.4%
H
11
13.8
|
L
 23.2%
H
9
13.8
|
L
 -17.2%
H
9
17.5
|
L
 -17.2%
H
9
17.5
|
L
 -17.2%
H
9
17.5
|
L
 -17.2%
H
9
17.5
|
L
 -17.2%
H
9
17.5
|
| Generate Biomedicines Inc |
|
886.1
|
13.7
|
L
 0.6%
H
13.4
14.7
|
L
 3.9%
H
12.8
15.9
|
L
 14.4%
H
11.1
15.9
|
L
 8.0%
H
11
15.9
|
L
 8.0%
H
11
15.9
|
L
 8.0%
H
11
15.9
|
L
 8.0%
H
11
15.9
|
L
 8.0%
H
11
15.9
|
| Kailera Therapeutics Inc |
|
2,781.2
|
21.5
|
L
 -4.5%
H
21.2
24.3
|
L
 -14.6%
H
21.2
25.7
|
L
 -17.4%
H
20.9
28.2
|
L
 -17.4%
H
20.9
28.2
|
L
 -17.4%
H
20.9
28.2
|
L
 -17.4%
H
20.9
28.2
|
L
 -17.4%
H
20.9
28.2
|
L
 -17.4%
H
20.9
28.2
|
| Hemab Therapeutics Holdings |
|
1,173.2
|
25.1
|
L
 -2.4%
H
24.6
26.6
|
L
 -26.1%
H
23.5
32
|
L
 -26.1%
H
23.5
32
|
L
 -26.1%
H
23.5
32
|
L
 -26.1%
H
23.5
32
|
L
 -26.1%
H
23.5
32
|
L
 -26.1%
H
23.5
32
|
L
 -26.1%
H
23.5
32
|